Early treatments for COVID-19

Bisht et al., Revisiting liquorice (Glycyrrhiza glabra L.) as anti-inflammatory, antivirals and immunomodulators: potential pharmacological applications with mechanistic insight., Phytomedicine Plus, doi:10.1016/j.phyplu.2021.100206

Khorshiddoust et al., Efficacy of a multiple-indication antiviral herbal drug (Saliravira®) for COVID-19 outpatients: A pre-clinical and randomized clinical trial study, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.112729

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

Mousavi et al., Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies, Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2022/2044282

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

https://www.mdpi.com/1999-4915/13/4/609/pdf

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227143/

https://pubmed.ncbi.nlm.nih.gov/33918301/

https://www.sciencedirect.com/science/article/pii/S2667031321000257

https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04706-3

https://dergipark.org.tr/en/pub/jcm/issue/71238/1165597

https://www.sciencedirect.com/science/article/abs/pii/S0022286022022876

https://www.frontiersin.org/articles/10.3389/fphar.2021.631206/full

https://www.mdpi.com/2223-7747/10/12/2600

https://www.jcchems.com/index.php/JCCHEMS/article/download/1802/561

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Wu et al., Protease inhibitor Camostat Mesyalte blocks wild type SARS-CoV-2 and D614G viral entry in human engineered miniature lungs, Biomaterials, doi:10.1016/j.biomaterials.2022.121509

Saloni et al., A computational study of potential therapeutics for COVID-19 invoking conceptual density functional theory, Structural Chemistry, doi:10.1007/s11224-022-02048-1

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

https://arxiv.org/abs/2108.13764ANIMAL:https://journals.asm.org/doi/full/10.1128/mBio.0097.. (In Silico)

https://www.sciencedirect.com/science/article/pii/S2352396421000487 (In Vitro)

https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00048-7/fulltext

https://www.europeanpharmaceuticalreview.com/news/159375/camostat-cuts-recovery-time-in-ha..

https://clinicaltrials.gov/ct2/show/NCT04530617

https://www.medrxiv.org/content/10.1101/2020.12.10.20240689v1.full

https://www.medrxiv.org/content/10.1101/2022.01.28.22270035v1.full

https://www.frontiersin.org/articles/10.3389/fphar.2022.870493/full

https://www.medrxiv.org/content/10.1101/2022.03.27.22271988v1.full

https://journals.asm.org/doi/10.1128/spectrum.03331-22

https://academic.oup.com/pcm/advance-article/doi/10.1093/pcmedi/pbac024/6713978

Srus et al., In Silico study of Wheatgrass constituents against Coronavirus COVID-19 Proteins., Research Square, doi:10.21203/rs.3.rs-1167417/v1

Chen et al., The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion, Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.11.022

Amalia et al., The Potential of Phyllanthus Niruri Plant Secondary Metabolites in Providing Antiviral Protection Against Sars-Cov-2: A Literature Review, KnE Medicine, doi:10.18502/kme.v2i3.11915

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Zhu et al., Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E, Virology, doi:10.1016/j.virol.2022.04.005

Adem et al., Multidimensional in silico strategy for identification of natural polyphenols-based SARS-CoV-2 main protease (Mpro) inhibitors to unveil a hope against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105452

HELALİ et al., Natural substances and coronavirus: review and potential for the inhibition of SARS-CoV-2, Current Perspectives on Medicinal and Aromatic Plants (CUPMAP), doi:10.38093/cupmap.1029572

https://www.tandfonline.com/doi/abs/10.1080/07391102.2022.2142297

https://digitalcommons.pcom.edu/research_day/research_day_GA_2022/researchGA2022/20/

https://www.sciencedirect.com/science/article/pii/S0223523421007066

https://www.mdpi.com/1424-8247/14/9/892

https://www.mdpi.com/2304-8158/10/9/2084/htm

Chober et al., Improved survival in intensive care unit in severe COVID-19 associated with amantadine use - retrospective study, International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.09.026

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

https://www.nature.com/articles/s42003-021-02866-9

https://www.nature.com/articles/s41594-020-00536-8

https://www.researchsquare.com/article/rs-121743/v1

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063946/

https://www.nature.com/articles/s41392-021-00558-8

https://pubmed.ncbi.nlm.nih.gov/33344913/

https://www.sciencedirect.com/science/article/pii/S092485792030162X

https://www.eurekaselect.com/183729/article

https://link.springer.com/article/10.1007/s43440-021-00231-5

https://link.springer.com/article/10.1007/s40268-021-00351-6

https://www.researchsquare.com/article/rs-493154/v1

Badraoui et al., Antiviral Effects of Artemisinin and Its Derivatives against SARS-CoV-2 Main Protease: Computational Evidences and Interactions with ACE2 Allelic Variants, Pharmaceuticals, doi:10.3390/ph15020129

Ahmad et al., Artemisia annua L. and Its Derivatives: Their Antiviral Effects on COVID-19 and Possible Mechanisms, Journal of Exploratory Research in Pharmacology, doi:10.14218/JERP.2021.00034

Tang et al., Network pharmacology-based predictions of active components and pharmacological mechanisms of Artemisia annua L. for the treatment of the novel Corona virus disease 2019 (COVID-19), BMC Complementary Medicine and Therapies, doi:10.1186/s12906-022-03523-2

Gurung et al., Artesunate induces substantial topological alterations in the SARS-CoV-2 Nsp1 protein structure, Journal of King Saud University - Science, doi:10.1016/j.jksus.2021.101810

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

https://www.sciencedirect.com/science/article/abs/pii/S0378874121002439

https://chemrxiv.org/engage/chemrxiv/article-details/60c74a53469df45440f43d21

https://www.openaccessjournals.com/articles/targeting-tgf-pathway-with-covid19-drug-candid..

https://www.biorxiv.org/content/10.1101/2021.09.08.459260v1 (In Vitro)

https://www.biorxiv.org/content/10.1101/2020.04.13.039917v3 (In Vitro)

https://linkinghub.elsevier.com/retrieve/pii/S0378874121002439

https://pubmed.ncbi.nlm.nih.gov/34306988/

https://clinicaltrials.gov/ct2/show/NCT04530617

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Gangadharan et al., Repurposing of Potential Antiviral Drugs against RNA-dependent RNA Polymerase of SARS-CoV-2 by Computational Approach, Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.09.007

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947

https://onlinelibrary.wiley.com/doi/full/10.1002/iid3.502

https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05698-w

https://www.mdpi.com/1999-4915/13/8/1665

https://www.newindianexpress.com/nation/2021/sep/15/clinical-trial-of-anti-viral-drug-umif..

https://academic.oup.com/pcm/advance-article/doi/10.1093/pcmedi/pbac024/6713978

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Babu et al., Identification of differentially expressed genes and their major pathways among the patient with COVID-19, cystic fibrosis, and chronic kidney disease, Informatics in Medicine Unlocked, doi:10.1016/j.imu.2022.101038

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Adem et al., Multidimensional in silico strategy for identification of natural polyphenols-based SARS-CoV-2 main protease (Mpro) inhibitors to unveil a hope against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105452

Ali et al., Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2, Archiv der Pharmazie, doi:10.1002/ardp.202100360

HELALİ et al., Natural substances and coronavirus: review and potential for the inhibition of SARS-CoV-2, Current Perspectives on Medicinal and Aromatic Plants (CUPMAP), doi:10.38093/cupmap.1029572

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

https://www.mdpi.com/2072-6643/13/8/2800

https://www.sciencedirect.com/science/article/pii/S0223523421007066

https://www.mdpi.com/2304-8158/10/9/2084/htm

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Shah et al., In silico studies on therapeutic agents for COVID-19: Drug repurposing approach, Life Sciences, doi:10.1016/j.lfs.2020.117652

Mousavi et al., Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies, Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2022/2044282

Mavlankar et al., Interaction of surface glycoprotein of SARS-CoV-2 variants of concern with potential drug candidates: A molecular docking study, F1000Research, doi:10.12688/f1000research.109586.1

Arshad et al., Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1909

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Davarpanah et al., Combination of Spironolactone and Sitagliptin Improves Clinical Outcomes of Outpatients with COVID-19: An Observational Study, medRxiv, doi:10.1101/2022.01.21.22269322

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

https://academic.oup.com/pcm/advance-article/doi/10.1093/pcmedi/pbac024/6713978

Munafò et al., Quercetin and Luteolin Are Single-digit Micromolar Inhibitors of the SARS-CoV-2 RNA-dependent RNA Polymerase, Research Square, doi:10.21203/rs.3.rs-1149846/v1

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Shahhamzehei et al., In Silico and In Vitro Identification of Pan-Coronaviral Main Protease Inhibitors from a Large Natural Product Library, Pharmaceuticals, doi:10.3390/ph15030308

Ali et al., Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2, Archiv der Pharmazie, doi:10.1002/ardp.202100360

HELALİ et al., Natural substances and coronavirus: review and potential for the inhibition of SARS-CoV-2, Current Perspectives on Medicinal and Aromatic Plants (CUPMAP), doi:10.38093/cupmap.1029572

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

https://pubmed.ncbi.nlm.nih.gov/34236507/ (In Silico)

https://www.sciencedirect.com/science/article/pii/S0223523421007066

https://www.mdpi.com/2304-8158/10/9/2084/htm

Milton-Laskibar et al., Potential usefulness of Mediterranean diet polyphenols against COVID-19-induced inflammation: a review of the current knowledge, Journal of Physiology and Biochemistry, doi:10.1007/s13105-022-00926-0

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Mortezaei et al., Variations of SARS-CoV-2 in the Iranian Population and Candidate Putative Drug-like Compounds to Inhibit the Mutated Proteins, Heliyon, doi:10.1016/j.heliyon.2022.e09910

Ali et al., Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2, Archiv der Pharmazie, doi:10.1002/ardp.202100360

https://www.medrxiv.org/content/10.1101/2020.07.21.20151423v1 (Retrospective Study)

https://www.mdpi.com/2076-3921/10/9/1440

https://www.tandfonline.com/doi/full/10.1080/21623945.2021.1965315

https://www.sciencedirect.com/science/article/pii/S0223523421007066

https://www.mdpi.com/2304-8158/10/9/2084/htm

https://www.sciencedirect.com/science/article/pii/S0308814621026005

Bronte et al., Baricitinib restrains the immune dysregulation in patients with severe COVID-19, Journal of Clinical Investigation, doi:10.1172/JCI141772

Stebbing et al., JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality, Science Advances, doi:10.1126/sciadv.abe4724

Goletti et al., Baricitinib Therapy in Covid-19 Pneumonia — An Unmet Need Fulfilled, New England Journal of Medicine, doi:10.1056/NEJMe2034982

Melikhov et al., Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals, Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2021-220049

Mavlankar et al., Interaction of surface glycoprotein of SARS-CoV-2 variants of concern with potential drug candidates: A molecular docking study, F1000Research, doi:10.12688/f1000research.109586.1

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Pillaiyar et al., Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy, Journal of Medicinal Chemistry, doi:10.1021/acs.jmedchem.1c00335

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947

https://www.sciencedirect.com/science/article/abs/pii/S2213260021003313

https://www.sciencedirect.com/science/article/abs/pii/S0954611122002517

Azeem et al., Virtual screening of phytochemicals by targeting multiple proteins of severe acute respiratory syndrome coronavirus 2: Molecular docking and molecular dynamics simulation studies, International Journal of Immunopathology and Pharmacology, doi:10.1177/03946320221142793

BİLGİNER et al., Molecular Docking Study of Several Seconder Metabolites from Medicinal Plants as Potential Inhibitors of COVID-19 Main Protease, Turkish Journal of Pharmaceutical Sciences, doi:10.4274/tjps.galenos.2021.83548

Jamshidnia et al., An Update on Promising Agents against COVID-19: Secondary Metabolites and Mechanistic Aspects, Current Pharmaceutical Design, doi:10.2174/1381612828666220722124826

Liu et al., Network Pharmacology and Molecular Docking Elucidate the Underlying Pharmacological Mechanisms of the Herb Houttuynia cordata in Treating Pneumonia Caused by SARS-CoV-2, Viruses, doi:10.3390/v14071588

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Chaves et al., Commercially Available Flavonols Are Better SARS-CoV-2 Inhibitors Than Isoflavone and Flavones, Viruses, doi:10.3390/v14071458

Zhu et al., Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E, Virology, doi:10.1016/j.virol.2022.04.005

HELALİ et al., Natural substances and coronavirus: review and potential for the inhibition of SARS-CoV-2, Current Perspectives on Medicinal and Aromatic Plants (CUPMAP), doi:10.38093/cupmap.1029572

https://journals.sagepub.com/doi/full/10.1177/1934578X221124769

https://www.mdpi.com/2304-8158/10/9/2084/htm

Milton-Laskibar et al., Potential usefulness of Mediterranean diet polyphenols against COVID-19-induced inflammation: a review of the current knowledge, Journal of Physiology and Biochemistry, doi:10.1007/s13105-022-00926-0

Aati et al., Garcinia cambogia Phenolics as Potent Anti-COVID-19 Agents: Phytochemical Profiling, Biological Activities, and Molecular Docking, Plants, doi:10.3390/plants11192521

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

BHARDWAJ et al., Molecular Docking Studies to Identify Promising Natural Inhibitors Targeting SARS-CoV-2 Nsp10-Nsp16 Protein Complex, Turkish Journal of Pharmaceutical Sciences, doi:10.4274/tjps.galenos.2021.56957

Ali et al., Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2, Archiv der Pharmazie, doi:10.1002/ardp.202100360

HELALİ et al., Natural substances and coronavirus: review and potential for the inhibition of SARS-CoV-2, Current Perspectives on Medicinal and Aromatic Plants (CUPMAP), doi:10.38093/cupmap.1029572

https://digitalcommons.pcom.edu/research_day/research_day_GA_2022/researchGA2022/20/

https://www.mdpi.com/2304-8158/10/9/2084/htm

Shah et al., In silico studies on therapeutic agents for COVID-19: Drug repurposing approach, Life Sciences, doi:10.1016/j.lfs.2020.117652

Mousavi et al., Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies, Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2022/2044282

Arshad et al., Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1909

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Davarpanah et al., Combination of Spironolactone and Sitagliptin Improves Clinical Outcomes of Outpatients with COVID-19: An Observational Study, medRxiv, doi:10.1101/2022.01.21.22269322

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

https://academic.oup.com/pcm/advance-article/doi/10.1093/pcmedi/pbac024/6713978

Péricat et al., Antiviral and Anti-Inflammatory Activities of Fluoxetine in a SARS-CoV-2 Infection Mouse Model, International Journal of Molecular Sciences, doi:10.3390/ijms232113623

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

https://www.tandfonline.com/doi/full/10.1080/22221751.2020.1829082

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3896539

https://www.nature.com/articles/s41598-021-85049-0

https://pubmed.ncbi.nlm.nih.gov/32975484/

Ravindran et al., Discovery of host-directed modulators of virus infection by probing the SARS-CoV-2–host protein–protein interaction network, Briefings in Bioinformatics, doi:10.1093/bib/bbac456

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

https://www.mdpi.com/1999-4915/13/9/1768 (In Vitro)

https://journals.asm.org/doi/full/10.1128/mBio.00970-21 (Animal Study)

https://www.biorxiv.org/content/10.1101/2021.07.08.451654v1 (Animal Study)

https://www.sciencedirect.com/science/article/pii/S2589537021004491 (RCT)

https://journals.asm.org/doi/10.1128/spectrum.03331-22

https://academic.oup.com/pcm/advance-article/doi/10.1093/pcmedi/pbac024/6713978

Jitobaom et al., Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations, BMC Pharmacology and Toxicology, doi:10.1186/s40360-022-00580-8

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Wang et al., Screening Potential Drugs for COVID-19 Based on Bound Nuclear Norm Regularization, Frontiers in Genetics, doi:10.3389/fgene.2021.749256

Arshad et al., Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1909

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Gassen et al., SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals, Nature Communications, doi:10.1038/s41467-021-24007-w

Basu et al., Therapeutics for COVID-19 and post COVID-19 complications: An update, Current Research in Pharmacology and Drug Discovery, doi:10.1016/j.crphar.2022.100086

Mirabelli et al., Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2105815118

https://www.sciencedirect.com/science/article/pii/S2049080121007299doi:10.1111/bph.15843

Risner et al., Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture, bioRxiv, doi:10.1101/2020.08.12.246389

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

https://www.sciencedirect.com/science/article/pii/S2352906721001639

https://onlinelibrary.wiley.com/doi/10.1111/ijcp.14434 (Retrospective Study)

https://www.mdpi.com/1999-4915/13/10/2084

Chen et al., The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion, Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.11.022

Talluri, S., Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19, Combinatorial Chemistry & High Throughput Screening, doi:10.2174/1386207323666200814132149

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

https://academic.oup.com/pcm/advance-article/doi/10.1093/pcmedi/pbac024/6713978

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Mavlankar et al., Interaction of surface glycoprotein of SARS-CoV-2 variants of concern with potential drug candidates: A molecular docking study, F1000Research, doi:10.12688/f1000research.109586.1

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Chellasamy et al., Docking and molecular dynamics studies of human ezrin protein with a modelled SARS-CoV-2 endodomain and their interaction with potential invasion inhibitors, Journal of King Saud University - Science, doi:10.1016/j.jksus.2022.102277

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Nandi et al., Repurposing of Drugs and HTS to Combat SARS-CoV-2 Main Protease Utilizing Structure-Based Molecular Docking, Letters in Drug Design & Discovery, doi:10.2174/1570180818666211007111105

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Park et al., Epigallocatechin Gallate (EGCG), a Green Tea Polyphenol, Reduces Coronavirus Replication in a Mouse Model, Viruses, doi:10.3390/v13122533

Azeem et al., Virtual screening of phytochemicals by targeting multiple proteins of severe acute respiratory syndrome coronavirus 2: Molecular docking and molecular dynamics simulation studies, International Journal of Immunopathology and Pharmacology, doi:10.1177/03946320221142793

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Ali et al., Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2, Archiv der Pharmazie, doi:10.1002/ardp.202100360

https://www.sciencedirect.com/science/article/pii/S0223523421007066

https://www.mdpi.com/1424-8247/14/9/892

https://www.mdpi.com/2304-8158/10/9/2084/htm

https://www.sciencedirect.com/science/article/pii/S0308814621026005

Haritha et al., Quantum chemical studies on the binding domain of SARS-CoV-2 S-protein: human ACE2 interface complex, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2022.2120537

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Chaves et al., Commercially Available Flavonols Are Better SARS-CoV-2 Inhibitors Than Isoflavone and Flavones, Viruses, doi:10.3390/v14071458

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

HELALİ et al., Natural substances and coronavirus: review and potential for the inhibition of SARS-CoV-2, Current Perspectives on Medicinal and Aromatic Plants (CUPMAP), doi:10.38093/cupmap.1029572

https://digitalcommons.pcom.edu/research_day/research_day_GA_2022/researchGA2022/20/

https://www.mdpi.com/1424-8247/14/9/892

https://www.mdpi.com/2304-8158/10/9/2084/htm

Hernández et al., Ozone therapy for patients with COVID-19 pneumonia: Preliminary report of a prospective case-control study, International Immunopharmacology, doi:10.1016/j.intimp.2020.107261

Shah et al., Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: A phase 1/11 randomized control trial (SEOT study), International Immunopharmacology, doi:10.1016/j.intimp.2020.107301

Tascini et al., Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience, Internal and Emergency Medicine, doi:10.1007/s11739-020-02542-6

Araimo et al., Ozone as adjuvant support in the treatment of COVID‐19: A preliminary report of probiozovid trial, Journal of Medical Virology, doi:10.1002/jmv.26636

Fernández-Cuadros et al., Compassionate Use of Rectal Ozone (O3) in Severe COVID-19 Pneumonia: a Case-Control Study, SN Comprehensive Clinical Medicine, doi:10.1007/s42399-021-00849-9

Sozio et al., CORonavirus-19 mild to moderate pneumonia Management with blood Ozonization in patients with Respiratory failure (CORMOR) multicentric prospective randomized clinical trial, International Immunopharmacology, doi:10.1016/j.intimp.2021.107874

Fernández-Cuadros et al., Effect of Rectal Ozone (O3) in Severe COVID-19 Pneumonia: Preliminary Results, SN Comprehensive Clinical Medicine, doi:10.1007/s42399-020-00374-1

https://jppres.com/jppres/ozone-in-covid-19/

Kushari et al., An integrated computational approach towards the screening of active plant metabolites as potential inhibitors of SARS-CoV-2: an overview, Structural Chemistry, doi:10.1007/s11224-022-02066-z

Liu et al., Network Pharmacology and Molecular Docking Elucidate the Underlying Pharmacological Mechanisms of the Herb Houttuynia cordata in Treating Pneumonia Caused by SARS-CoV-2, Viruses, doi:10.3390/v14071588

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

HELALİ et al., Natural substances and coronavirus: review and potential for the inhibition of SARS-CoV-2, Current Perspectives on Medicinal and Aromatic Plants (CUPMAP), doi:10.38093/cupmap.1029572

https://www.tandfonline.com/doi/abs/10.1080/07391102.2022.2142297

https://www.mdpi.com/2304-8158/10/9/2084/htm

Patten et al., Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization., iScience, doi:10.1016/j.isci.2022.104925

Kumar et al., Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection, Virology, doi:10.1016/j.virol.2022.05.004

Riva et al., A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals, bioRxiv, doi:10.1101/2020.04.16.044016

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

Basu et al., Therapeutics for COVID-19 and post COVID-19 complications: An update, Current Research in Pharmacology and Drug Discovery, doi:10.1016/j.crphar.2022.100086

Pillaiyar et al., Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy, Journal of Medicinal Chemistry, doi:10.1021/acs.jmedchem.1c00335

https://academic.oup.com/pcm/advance-article/doi/10.1093/pcmedi/pbac024/6713978

Hinks et al., Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial, The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00263-0

Butler et al., Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial, The Lancet, doi:10.1016/S0140-6736(21)00461-X

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Mousavi et al., Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies, Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2022/2044282

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Monserrat Villatoro et al., A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis, Pharmaceuticals, doi:10.3390/ph15010078

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Azeem et al., Virtual screening of phytochemicals by targeting multiple proteins of severe acute respiratory syndrome coronavirus 2: Molecular docking and molecular dynamics simulation studies, International Journal of Immunopathology and Pharmacology, doi:10.1177/03946320221142793

Xu et al., An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges, Biochemical Pharmacology, doi:10.1016/j.bcp.2022.115279

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

https://www.karger.com/Article/Abstract/519564

https://www.mdpi.com/2304-8158/10/9/2084/htm

Li et al., Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2, Computational and Structural Biotechnology Journal, doi:10.1016/j.csbj.2020.08.016

Ke et al., Artificial intelligence approach fighting COVID-19 with repurposing drugs, Biomedical Journal, doi:10.1016/j.bj.2020.05.001

Mody et al., Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents, Communications Biology, doi:10.1038/s42003-020-01577-x

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Davarpanah et al., Combination of Spironolactone and Sitagliptin Improves Clinical Outcomes of Outpatients with COVID-19: An Observational Study, medRxiv, doi:10.1101/2022.01.21.22269322

https://www.sciencedirect.com/science/article/pii/S259009862200029X

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

https://journals.physiology.org/doi/full/10.1152/ajplung.00153.2020

https://www.biorxiv.org/content/10.1101/2021.04.08.439071v1

https://physoc.onlinelibrary.wiley.com/doi/full/10.14814/phy2.14707

Shah et al., In silico studies on therapeutic agents for COVID-19: Drug repurposing approach, Life Sciences, doi:10.1016/j.lfs.2020.117652

Xu et al., An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges, Biochemical Pharmacology, doi:10.1016/j.bcp.2022.115279

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

http://hdl.handle.net/10523/13405

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Xu et al., An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges, Biochemical Pharmacology, doi:10.1016/j.bcp.2022.115279

Wang et al., Screening Potential Drugs for COVID-19 Based on Bound Nuclear Norm Regularization, Frontiers in Genetics, doi:10.3389/fgene.2021.749256

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

https://academic.oup.com/pcm/advance-article/doi/10.1093/pcmedi/pbac024/6713978

Hsu et al., The effect of sofosbuvir-based treatment on the clinical outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials, International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2022.106545

Sokhela et al., Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection, Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkac266

Xu et al., An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges, Biochemical Pharmacology, doi:10.1016/j.bcp.2022.115279

Yakoot et al., Clinical utility of repurposing a short course of hepatitis C drugs for COVID19. A randomized controlled study, medRxiv, doi:10.1101/2022.07.18.22277477

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Medhat et al., Sofosbuvir/Ledipasvir in Combination or Nitazoxanide Alone are Safe and Efficient Treatments for COVID-19 Infection: A Randomized Controlled Trial for Repurposing antivirals, Arab Journal of Gastroenterology, doi:10.1016/j.ajg.2022.04.005

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

Sa-ngiamsuntorn et al., Anti-SARS-CoV-2 Activity of Andrographis paniculata Extract and Its Major Component Andrographolide in Human Lung Epithelial Cells and Cytotoxicity Evaluation in Major Organ Cell Representatives, Journal of Natural Products, doi:10.1021/acs.jnatprod.0c01324

Wanaratna et al., Efficacy and safety of Andrographis paniculata extract in patients with mild COVID-19: A randomized controlled trial, medRxiv, doi:10.1101/2021.07.08.21259912

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Chaves et al., Atazanavir is a competitive inhibitor of SARS-CoV-2 Mpro, impairing variants replication in vitro and in vivo, bioRxiv, doi:10.1101/2021.11.24.469775

Beck et al., Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model, Computational and Structural Biotechnology Journal, doi:10.1016/j.csbj.2020.03.025

Arshad et al., Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1909

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947

https://academic.oup.com/pcm/advance-article/doi/10.1093/pcmedi/pbac024/6713978

Zhou et al., Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, Cell Discovery, doi:10.1038/s41421-020-0153-3

Cousins et al., Integrative analysis of viral entry networks and clinical outcomes identifies a protective role for spironolactone in severe COVID-19, medRxiv, doi:10.1101/2022.07.02.22277181

Abdel-Halim et al., Identification of Drug Combination Therapies for SARS-CoV-2: A Molecular Dynamics Simulations Approach, Drug Design, Development and Therapy, doi:10.2147/DDDT.S366423

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286244/pdf/main.pdf

https://www.mdpi.com/1424-8247/14/3/226

Dinda et al., Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19, European Journal of Medicinal Chemistry Reports, doi:10.1016/j.ejmcr.2022.100079

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Kumar et al., Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection, Virology, doi:10.1016/j.virol.2022.05.004

Zhang et al., A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-020-00343-z

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

https://www.sciencedirect.com/science/article/pii/S2213422021000688

Sokhela et al., Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection, Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkac266

Xu et al., An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges, Biochemical Pharmacology, doi:10.1016/j.bcp.2022.115279

Yakoot et al., Clinical utility of repurposing a short course of hepatitis C drugs for COVID19. A randomized controlled study, medRxiv, doi:10.1101/2022.07.18.22277477

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Mosharaf et al., Computational identification of host genomic biomarkers highlighting their functions, pathways and regulators that influence SARS-CoV-2 infections and drug repurposing, Scientific Reports, doi:10.1038/s41598-022-08073-8

Wang et al., Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture, Communications Biology, doi:10.1038/s42003-022-03101-9

Dhar et al., Doxycycline for the prevention of progression of COVID-19 to severe disease requiring intensive care unit (ICU) admission: a randomized, controlled, open-label, parallel group trial (DOXPREVENT.ICU), medRxiv, doi:10.1101/2022.01.30.22269685

Rehman et al., In Silico molecular docking and dynamic analysis of natural compounds against major non-structural proteins of SARS-COV-2, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2022.2139766

Mousavi et al., Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies, Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2022/2044282

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Nandi et al., Repurposing of Drugs and HTS to Combat SARS-CoV-2 Main Protease Utilizing Structure-Based Molecular Docking, Letters in Drug Design & Discovery, doi:10.2174/1570180818666211007111105

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

https://www.mdpi.com/2304-8158/10/9/2084/htm

https://www.sciencedirect.com/science/article/pii/S0308814621026005

Zhou et al., Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, Cell Discovery, doi:10.1038/s41421-020-0153-3

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Jang et al., Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2024302118

https://www.sciencedirect.com/science/article/pii/S0223523421007066

https://www.sciencedirect.com/science/article/pii/S2213422021000688

https://pubmed.ncbi.nlm.nih.gov/32463221/

https://pubmed.ncbi.nlm.nih.gov/32992775/

https://pubmed.ncbi.nlm.nih.gov/32708578/

https://pubmed.ncbi.nlm.nih.gov/33336769/

https://pubmed.ncbi.nlm.nih.gov/33117175/

https://pubmed.ncbi.nlm.nih.gov/32322478/

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Jang et al., Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2024302118

Shahhamzehei et al., In Silico and In Vitro Identification of Pan-Coronaviral Main Protease Inhibitors from a Large Natural Product Library, Pharmaceuticals, doi:10.3390/ph15030308

https://www.mdpi.com/2304-8158/10/9/2084/htm

Oh et al., Network Pharmacology Study to Elucidate the Key Targets of Underlying Antihistamines against COVID-19, Current Issues in Molecular Biology, doi:10.3390/cimb44040109

Monserrat Villatoro et al., A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis, Pharmaceuticals, doi:10.3390/ph15010078

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889471/ (In Vitro)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713548/ (Retrospective Study)

https://jcmimagescasereports.org/article/JCM-V1-1016.pdf

https://www.sciencedirect.com/science/article/abs/pii/S1094553921000018 (Retrospective Study)

Schälter et al., Does methotrexate influence COVID-19 infection? Case series and mechanistic data, Arthritis Research & Therapy, doi:10.1186/s13075-021-02464-4

Caruso et al., Methotrexate inhibits SARS‐CoV‐2 virus replication “in vitro”, Journal of Medical Virology, doi:10.1002/jmv.26512

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

https://www.sciencedirect.com/science/article/abs/pii/S0952327821000132

https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-021-02795-5

https://www.authorea.com/doi/full/10.22541/au.161051252.26168891

https://www.sciencedirect.com/science/article/pii/S2589004221010087

https://www.plefa.com/article/S0952-3278(21)00013-2/fulltext

https://www.nature.com/articles/s41598-021-91794-z

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Zhou et al., Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, Cell Discovery, doi:10.1038/s41421-020-0153-3

Doshi et al., A computational approach to drug repurposing using graph neural networks, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105992

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

https://ccforum.biomedcentral.com/articles/10.1186/s13054-021-03648-9 (Retrospective Study)

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8242279/

https://pubmed.ncbi.nlm.nih.gov/33817670/

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7428453/

https://www.cureus.com/articles/43909-potential-role-of-xylitol-plus-grapefruit-seed-extra..

https://probiologists.com/Uploads/Articles/11_637497463703161509.pdf

https://www.biorxiv.org/content/10.1101/2020.12.02.408575v3.full.pdf

https://www.businesswire.com/news/home/20211222005383/en/

https://www.researchgate.net/publication/347176706_A_Nasal_Spray_Solution_of_Grapefruit_Se..

https://www.precisionvaccinations.com/nasal-spray-may-eliminate-sars-cov-2-virus

Jeong et al., Rapid discovery and classification of inhibitors of coronavirus infection by pseudovirus screen and amplified luminescence proximity homogeneous assay, Antiviral Research, doi:10.1016/j.antiviral.2022.105473

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

Mirabelli et al., Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2105815118

https://www.mdpi.com/1424-8247/14/3/226

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

https://www.biorxiv.org/content/10.1101/2021.09.10.459744v1.full.pdf (In Vitro)

https://clinicaltrials.gov/ct2/show/NCT04335136

https://www.sciencedirect.com/science/article/abs/pii/S0040595721002043

https://www.sciencedirect.com/science/article/pii/S0953620521003071

https://www.biorxiv.org/content/10.1101/2020.09.15.296228v1

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144927/

https://pubmed.ncbi.nlm.nih.gov/34052578/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713548/ (Retrospective Study)

https://www.researchsquare.com/article/rs-864566/v1

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

https://www.trialsitenews.com/a/new-oral-drug-for-covid-19first-indigenous-chinese-drug-ap..

10.1016/j.xinn.2022.100321

https://academic.oup.com/pcm/advance-article/doi/10.1093/pcmedi/pbac024/6713978

Xu et al., An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges, Biochemical Pharmacology, doi:10.1016/j.bcp.2022.115279

Dinda et al., Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19, European Journal of Medicinal Chemistry Reports, doi:10.1016/j.ejmcr.2022.100079

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

https://www.mdpi.com/1424-8247/14/9/892

Anderson et al., Virucidal activity of CPC-containing oral rinses against SARS-CoV-2 variants and are active in the presence of human saliva, bioRxiv, doi:10.1101/2021.08.05.455040

Okamoto et al., Virucidal activity and mechanism of action of cetylpyridinium chloride against SARS-CoV-2, bioRxiv, doi:10.1101/2022.01.27.477964

Okamoto et al., Virucidal activity and mechanism of action of cetylpyridinium chloride against SARS-CoV-2, Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology, doi:10.1016/j.ajoms.2022.04.001

https://www.biorxiv.org/content/10.1101/2020.10.28.359257v1 (In Vitro)

https://www.sciencedirect.com/science/article/pii/S0929664621004691 (Review)

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Dinda et al., Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19, European Journal of Medicinal Chemistry Reports, doi:10.1016/j.ejmcr.2022.100079

Patten et al., Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization., iScience, doi:10.1016/j.isci.2022.104925

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

https://www.researchsquare.com/article/rs-770724/v1

https://www.frontiersin.org/articles/10.3389/fphar.2021.660490/full

https://www.sciencedirect.com/science/article/pii/S2049080121009249

Liu et al., Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus, Bioinformatics, doi:10.1093/bioinformatics/btaa224

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

https://www.sciencedirect.com/science/article/abs/pii/S104620232100205X (In Silico)

https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts...

Azeem et al., Virtual screening of phytochemicals by targeting multiple proteins of severe acute respiratory syndrome coronavirus 2: Molecular docking and molecular dynamics simulation studies, International Journal of Immunopathology and Pharmacology, doi:10.1177/03946320221142793

Aati et al., Garcinia cambogia Phenolics as Potent Anti-COVID-19 Agents: Phytochemical Profiling, Biological Activities, and Molecular Docking, Plants, doi:10.3390/plants11192521

Youn et al., Robust therapeutic effects on COVID-19 of novel small molecules: Alleviation of SARS-CoV-2 S protein induction of ACE2/TMPRSS2, NOX2/ROS, and MCP-1, Frontiers in Cardiovascular Medicine, doi:10.3389/fcvm.2022.957340

https://www.sciencedirect.com/science/article/pii/S0223523421007066

https://www.mdpi.com/2304-8158/10/9/2084/htm

Burgos-Ramos et al., Is hydrogen peroxide an effective mouthwash for reducing the viral load of SARS-CoV-2 in dental clinics?, The Saudi Dental Journal, doi:10.1016/j.sdentj.2022.01.005

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308628/

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8289588/

https://www.sciencedirect.com/science/article/pii/S0929664621004691 (Review)

http://www.orthomolecular.org/resources/omns/v17n13.shtml

Drayman et al., Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2, Science, doi:10.1126/science.abg5827

Martínez‐Ortega et al., In Silico Characterization of Masitinib Interaction with SARS‐CoV‐2 Main Protease, ChemMedChem, doi:10.1002/cmdc.202100375

Drayman et al., Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro, bioRxiv, doi:10.1101/2020.08.31.274639

Ravindran et al., Discovery of host-directed modulators of virus infection by probing the SARS-CoV-2–host protein–protein interaction network, Briefings in Bioinformatics, doi:10.1093/bib/bbac456

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Cagno et al., Methylene Blue has a potent antiviral activity against SARS-CoV-2 and H1N1 influenza virus in the absence of UV-activation in vitro, Scientific Reports, doi:10.1038/s41598-021-92481-9

Ali et al., Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2, Archiv der Pharmazie, doi:10.1002/ardp.202100360

https://www.frontiersin.org/articles/10.3389/fphar.2020.600372/full

https://www.sciencedirect.com/science/article/pii/S0753332221008064

https://pubmed.ncbi.nlm.nih.gov/34019535/

Barberis et al., Understanding protection from SARS-CoV-2 using metabolomics, Scientific Reports, doi:10.1038/s41598-021-93260-2

Angeles-Agdeppa et al., Virgin coconut oil is effective in lowering C-reactive protein levels among suspect and probable cases of COVID-19, Journal of Functional Foods, doi:10.1016/j.jff.2021.104557

Preuss et al., Suggestions for Combatting COVID-19 by Natural Means in the Absence of Standard Medical Regimens, Journal of the American College of Nutrition, doi:10.1080/07315724.2020.1779554

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/..

Ur Rehman et al., Flavonoids and other polyphenols against SARS-CoV-2, Application of Natural Products in SARS-CoV-2, doi:10.1016/B978-0-323-95047-3.00014-9

Jamshidnia et al., An Update on Promising Agents against COVID-19: Secondary Metabolites and Mechanistic Aspects, Current Pharmaceutical Design, doi:10.2174/1381612828666220722124826

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

https://www.sciencedirect.com/science/article/pii/S0223523421007066

https://www.mdpi.com/2304-8158/10/9/2084/htm

Silveira et al., Efficacy of Brazilian green propolis (EPP-AF®) as an adjunct treatment for hospitalized COVID-19 patients: A randomized, controlled clinical trial, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2021.111526

Bilir et al., Evaluation of the Effect of Anatolian Propolis on Covid-19 in Healthcare Professionals, ScienceOpen, doi:10.14293/S2199-1006.1.SOR-.PPZR1OD.v1

https://www.medrxiv.org/content/10.1101/2021.01.08.20248932v1

https://www.scienceopen.com/hosted-document?doi=10.14293/S2199-1006.1.SOR-.PPZR1OD.v1

https://jtim.tums.ac.ir/index.php/jtim/article/view/408

Gaitán-Duarte et al., Effectiveness of Rosuvastatin plus Colchicine, Emtricitabine/Tenofovir and a combination of them in Hospitalized Patients with SARS Covid-19, medRxiv, doi:10.1101/2021.07.06.21260085

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

https://elifesciences.org/articles/68165

Mousavi et al., Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies, Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2022/2044282

Talluri, S., Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19, Combinatorial Chemistry & High Throughput Screening, doi:10.2174/1386207323666200814132149

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

Ma et al., Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CLpro, Antiviral Research, doi:10.1016/j.antiviral.2022.105419

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Lazniewski et al., Drug repurposing for identification of potential spike inhibitors for SARS-CoV-2 using molecular docking and molecular dynamics simulations, Methods, doi:10.1016/j.ymeth.2022.02.004

Kadioglu et al., Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2021.104359

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Xu et al., An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges, Biochemical Pharmacology, doi:10.1016/j.bcp.2022.115279

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

https://pubmed.ncbi.nlm.nih.gov/32513797/

https://pubmed.ncbi.nlm.nih.gov/33674802/

Manish et al., Computational molecular interaction between SARS-CoV-2 main protease and theaflavin digallate using free energy perturbation and molecular dynamics, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106125

Yang et al., Potential medicinal plants involved in inhibiting 3CLpro activity: A practical alternate approach to combating COVID-19, Journal of Integrative Medicine, doi:10.1016/j.joim.2022.08.001

Al-Sehemi et al., In Silico Exploration of Binding Potentials of Anti SARS-CoV-1 Phytochemicals against Main Protease of SARS-CoV-2, Journal of Saudi Chemical Society, doi:10.1016/j.jscs.2022.101453

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0253489

Pasla et al., In silico Drug Repurposing for the Identification of Antimalarial Drugs as Candidate Inhibitors of SARS-CoV-2, Anti-Infective Agents, doi:10.2174/2211352519666211202141143

https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009840

https://pubs.acs.org/doi/abs/10.1021/acsinfecdis.1c00278 (In Vitro)

https://www.medrxiv.org/content/10.1101/2022.05.24.22275411v1

Ravindran et al., Discovery of host-directed modulators of virus infection by probing the SARS-CoV-2–host protein–protein interaction network, Briefings in Bioinformatics, doi:10.1093/bib/bbac456

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Pillaiyar et al., Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy, Journal of Medicinal Chemistry, doi:10.1021/acs.jmedchem.1c00335

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Srivastava et al., The role of herbal plants in the inhibition of SARS-CoV-2 main protease: A computational approach, Journal of the Indian Chemical Society, doi:10.1016/j.jics.2022.100640

Ali et al., Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2, Archiv der Pharmazie, doi:10.1002/ardp.202100360

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

Ke et al., Artificial intelligence approach fighting COVID-19 with repurposing drugs, Biomedical Journal, doi:10.1016/j.bj.2020.05.001

Demarest et al., Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19, Antiviral Research, doi:10.1016/j.antiviral.2022.105403

Demarest et al., Brequinar and Dipyridamole in Combination Exhibits Synergistic Antiviral Activity Against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19, bioRxiv, doi:10.1101/2022.03.30.486499

https://journals.asm.org/doi/10.1128/spectrum.03331-22

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Ke et al., Artificial intelligence approach fighting COVID-19 with repurposing drugs, Biomedical Journal, doi:10.1016/j.bj.2020.05.001

Doshi et al., A computational approach to drug repurposing using graph neural networks, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105992

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713548/ (Retrospective Study)

https://www.nature.com/articles/s41392-021-00689-y (Retrospective Study)

https://www.sciencedirect.com/science/article/abs/pii/S1094553921000018 (Retrospective Study)

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Ke et al., Artificial intelligence approach fighting COVID-19 with repurposing drugs, Biomedical Journal, doi:10.1016/j.bj.2020.05.001

Arshad et al., Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1909

https://academic.oup.com/pcm/advance-article/doi/10.1093/pcmedi/pbac024/6713978

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

https://www.sciencedirect.com/science/article/pii/S0223523421007066

https://www.mdpi.com/2304-8158/10/9/2084/htm

Song et al., Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial, Journal of Clinical Medicine, doi:10.3390/jcm10163545

Clemency et al., Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19, JAMA Internal Medicine, doi:10.1001/jamainternmed.2021.6759

Mortezaei et al., Variations of SARS-CoV-2 in the Iranian Population and Candidate Putative Drug-like Compounds to Inhibit the Mutated Proteins, Heliyon, doi:10.1016/j.heliyon.2022.e09910

https://www.medrxiv.org/content/10.1101/2021.09.07.21261811v1

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Ke et al., Artificial intelligence approach fighting COVID-19 with repurposing drugs, Biomedical Journal, doi:10.1016/j.bj.2020.05.001

Mirabelli et al., Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2105815118

https://academic.oup.com/pcm/advance-article/doi/10.1093/pcmedi/pbac024/6713978

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Yin et al., Computational Screening of Repurposed Drugs Targeting Sars-Cov-2 Main Protease By Molecular Docking, Sudan Journal of Medical Sciences, doi:10.18502/sjms.v17i3.12125

Talluri, S., Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19, Combinatorial Chemistry & High Throughput Screening, doi:10.2174/1386207323666200814132149

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

http://journal.oiu.edu.sd/index.php/FMHS/article/view/2688

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Bahadur Gurung et al., An in silico approach unveils the potential of antiviral compounds in preclinical and clinical trials as SARS-CoV-2 Omicron inhibitors, Saudi Journal of Biological Sciences, doi:10.1016/j.sjbs.2022.103297

Zhang et al., A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-020-00343-z

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

Cho et al., Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19, Scientific Reports, doi:10.1038/s41598-020-72879-7

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

https://www.biorxiv.org/content/10.1101/2021.09.17.460613v1

https://academic.oup.com/pcm/advance-article/doi/10.1093/pcmedi/pbac024/6713978

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Pradhan et al., A state-of-the-art review on fucoidan as an antiviral agent to combat viral infections, Carbohydrate Polymers, doi:10.1016/j.carbpol.2022.119551

https://pubs.rsc.org/en/content/articlelanding/2020/fo/d0fo02017f/unauth

https://www.sciencedirect.com/science/article/pii/S2589014X20302450https://www.mdpi.com/16..

https://www.sciencedirect.com/science/article/abs/pii/S0144861721009541

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

https://www.mdpi.com/2304-8158/10/9/2084/htm

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Peng et al., Discovery of potential anti-SARS-CoV-2 drugs based on large-scale screening in vitro and effect evaluation in vivo, Science China Life Sciences, doi:10.1007/s11427-021-2031-7

Pillaiyar et al., Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy, Journal of Medicinal Chemistry, doi:10.1021/acs.jmedchem.1c00335

Mirabelli et al., Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2105815118

Kushari et al., An integrated computational approach towards the screening of active plant metabolites as potential inhibitors of SARS-CoV-2: an overview, Structural Chemistry, doi:10.1007/s11224-022-02066-z

Rajamanickam et al., Molecular insight of phytocompounds from Indian spices and its hyaluronic acid conjugates to block SARS-CoV-2 viral entry, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2022.2121757

Srivastava et al., The role of herbal plants in the inhibition of SARS-CoV-2 main protease: A computational approach, Journal of the Indian Chemical Society, doi:10.1016/j.jics.2022.100640

Nag et al., Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105552

Youn et al., Robust therapeutic effects on COVID-19 of novel small molecules: Alleviation of SARS-CoV-2 S protein induction of ACE2/TMPRSS2, NOX2/ROS, and MCP-1, Frontiers in Cardiovascular Medicine, doi:10.3389/fcvm.2022.957340

Choe et al., The Efficacy of Traditional Medicinal Plants in Modulating the Main Protease of SARS‐CoV‐2 and Cytokine Storm, Chemistry & Biodiversity, doi:10.1002/cbdv.202200655

Sharma et al., Nutraceuticals aid in managing COVID-19, World Journal of Pharmaceutical Sciences, doi:10.54037/WJPS.2022.100204

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Meng et al., Associations of habitual glucosamine use with SARS-CoV-2 infection and hospital admission and death with COVID-19: Evidence from a large population based cohort study, medRxiv, doi:10.1101/2022.09.05.22279621

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

https://pubmed.ncbi.nlm.nih.gov/34306677/

https://www.sciencedirect.com/science/article/pii/S2049080121005240

Choe et al., The Efficacy of Traditional Medicinal Plants in Modulating the Main Protease of SARS‐CoV‐2 and Cytokine Storm, Chemistry & Biodiversity, doi:10.1002/cbdv.202200655

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

HELALİ et al., Natural substances and coronavirus: review and potential for the inhibition of SARS-CoV-2, Current Perspectives on Medicinal and Aromatic Plants (CUPMAP), doi:10.38093/cupmap.1029572

https://www.jcchems.com/index.php/JCCHEMS/article/download/1802/561

Ke et al., Artificial intelligence approach fighting COVID-19 with repurposing drugs, Biomedical Journal, doi:10.1016/j.bj.2020.05.001

Dinda et al., Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19, European Journal of Medicinal Chemistry Reports, doi:10.1016/j.ejmcr.2022.100079

Patten et al., Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization., iScience, doi:10.1016/j.isci.2022.104925

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Giarratana et al., A sprayable Acid-Oxidizing solution containing hypochlorous acid (AOS2020) efficiently and safely inactivates SARS-Cov-2: a new potential solution for upper respiratory tract hygiene, European Archives of Oto-Rhino-Laryngology, doi:10.1007/s00405-021-06644-5

Takeda et al., Acidic electrolyzed water potently inactivates SARS-CoV-2 depending on the amount of free available chlorine contacting with the virus, Biochemical and Biophysical Research Communications, doi:10.1016/j.bbrc.2020.07.029

Mueller et al., A Concept for the Reduction of Mucosal SARS-CoV-2 Load using Hypochloric Acid Solutions, Drug Research, doi:10.1055/a-1467-5956

Rasmussen et al., Inhalation of a fog of hypochlorous acid (HOCl): Biochemical, antimicrobial, and pathological assessment, Research Square, doi:10.21203/rs.3.rs-1009101/v1

Ravindran et al., Discovery of host-directed modulators of virus infection by probing the SARS-CoV-2–host protein–protein interaction network, Briefings in Bioinformatics, doi:10.1093/bib/bbac456

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Shah et al., In silico studies on therapeutic agents for COVID-19: Drug repurposing approach, Life Sciences, doi:10.1016/j.lfs.2020.117652

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

https://academic.oup.com/pcm/advance-article/doi/10.1093/pcmedi/pbac024/6713978

https://www.mdpi.com/1999-4915/13/7/1301/htm

https://www.researchgate.net/publication/354035681_Theoretical_Discussion_of_the_Probable_..

https://www.researchgate.net/publication/345916326_Amino_Acid_L-Lysine_SARS-CoV-2_COVID-19..

https://www.researchgate.net/publication/344210822_Lysine_Therapy_for_SARS-CoV-2

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Arshad et al., Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1909

Pasla et al., In silico Drug Repurposing for the Identification of Antimalarial Drugs as Candidate Inhibitors of SARS-CoV-2, Anti-Infective Agents, doi:10.2174/2211352519666211202141143

https://academic.oup.com/pcm/advance-article/doi/10.1093/pcmedi/pbac024/6713978

Ravindran et al., Discovery of host-directed modulators of virus infection by probing the SARS-CoV-2–host protein–protein interaction network, Briefings in Bioinformatics, doi:10.1093/bib/bbac456

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Wang et al., Screening Potential Drugs for COVID-19 Based on Bound Nuclear Norm Regularization, Frontiers in Genetics, doi:10.3389/fgene.2021.749256

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Milton-Laskibar et al., Potential usefulness of Mediterranean diet polyphenols against COVID-19-induced inflammation: a review of the current knowledge, Journal of Physiology and Biochemistry, doi:10.1007/s13105-022-00926-0

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

https://www.mdpi.com/2304-8158/10/9/2084/htm

Lewnard et al., Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California, medRxiv, doi:10.1101/2022.01.11.22269045

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

https://pubmed.ncbi.nlm.nih.gov/32790936/

https://clinicaltrials.gov/ct2/show/NCT04583410

BİLGİNER et al., Molecular Docking Study of Several Seconder Metabolites from Medicinal Plants as Potential Inhibitors of COVID-19 Main Protease, Turkish Journal of Pharmaceutical Sciences, doi:10.4274/tjps.galenos.2021.83548

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

https://digitalcommons.pcom.edu/research_day/research_day_GA_2022/researchGA2022/20/

https://www.mdpi.com/2304-8158/10/9/2084/htm

Mody et al., Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents, Communications Biology, doi:10.1038/s42003-020-01577-x

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Kadioglu et al., Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2021.104359

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

Kadioglu et al., Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2021.104359

https://link.springer.com/article/10.1007/s11010-020-03981-7

https://psmpublishers.org/issues/the-use-of-fresh-pomegranate-juice-in-the-treatment-of-co..

https://www.sciencedirect.com/science/article/pii/S0045206821005228

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Nicastri et al., A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID-19, eClinicalMedicine, doi:10.1016/j.eclinm.2022.101450

Jeong et al., Rapid discovery and classification of inhibitors of coronavirus infection by pseudovirus screen and amplified luminescence proximity homogeneous assay, Antiviral Research, doi:10.1016/j.antiviral.2022.105473

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Chen et al., The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion, Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.11.022

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

https://pubmed.ncbi.nlm.nih.gov/32992282

https://www.sciencedirect.com/science/article/pii/S030698772031104X

https://www.sciencedirect.com/science/article/pii/S2405457721011074

https://www.mdpi.com/2072-6643/11/9/2101

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Yang et al., Potential medicinal plants involved in inhibiting 3CLpro activity: A practical alternate approach to combating COVID-19, Journal of Integrative Medicine, doi:10.1016/j.joim.2022.08.001

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

https://pubmed.ncbi.nlm.nih.gov/33415017/

https://www.sciencedirect.com/science/article/pii/S0753332222009507

Del Amo, J., Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers, medRxiv, doi:10.1101/2022.03.02.22271710

Polo et al., Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers, Clinical Microbiology and Infection, doi:10.1016/j.cmi.2022.07.006

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Dinda et al., Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19, European Journal of Medicinal Chemistry Reports, doi:10.1016/j.ejmcr.2022.100079

Zhang et al., A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-020-00343-z

https://www.sciencedirect.com/science/article/pii/S2213422021000688

Patel et al., Computational investigation of natural compounds as potential main protease (Mpro) inhibitors for SARS-CoV-2 virus, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106318

BHARDWAJ et al., Molecular Docking Studies to Identify Promising Natural Inhibitors Targeting SARS-CoV-2 Nsp10-Nsp16 Protein Complex, Turkish Journal of Pharmaceutical Sciences, doi:10.4274/tjps.galenos.2021.56957

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

https://digitalcommons.pcom.edu/research_day/research_day_GA_2022/researchGA2022/20/

Moreno-Pérez et al., El ácido valproico podría ayudar en la lucha contra el COVID-19: un estudio de casos y controles, Neurología, doi:10.1016/j.nrl.2022.01.007

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

Pham et al., A deep learning framework for high-throughput mechanism-driven phenotype compound screening and its application to COVID-19 drug repurposing, Nature Machine Intelligence, doi:10.1038/s42256-020-00285-9

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Wang et al., Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture, Communications Biology, doi:10.1038/s42003-022-03101-9

Kadioglu et al., Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2021.104359

Abdallah et al., Bio-Guided Isolation of SARS-CoV-2 Main Protease Inhibitors from Medicinal Plants: In Vitro Assay and Molecular Dynamics, Plants, doi:10.3390/plants11151914

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

Yang et al., Potential medicinal plants involved in inhibiting 3CLpro activity: A practical alternate approach to combating COVID-19, Journal of Integrative Medicine, doi:10.1016/j.joim.2022.08.001

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

Srivastava et al., The role of herbal plants in the inhibition of SARS-CoV-2 main protease: A computational approach, Journal of the Indian Chemical Society, doi:10.1016/j.jics.2022.100640

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Jose et al., Potential of phytocompounds from Brassica oleracea targeting S2-domain of SARS-CoV-2 spike glycoproteins: Structure and molecular insights, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.132369

Basu et al., Therapeutics for COVID-19 and post COVID-19 complications: An update, Current Research in Pharmacology and Drug Discovery, doi:10.1016/j.crphar.2022.100086

https://www.astrazeneca.com/media-centre/press-releases/2021/azd7442-prophylaxis-trial-met..

https://trialsitenews.com/astrazeneca-files-request-for-emergency-use-authorization-for-lo..

Ke et al., Artificial intelligence approach fighting COVID-19 with repurposing drugs, Biomedical Journal, doi:10.1016/j.bj.2020.05.001

Nandi et al., Repurposing of Drugs and HTS to Combat SARS-CoV-2 Main Protease Utilizing Structure-Based Molecular Docking, Letters in Drug Design & Discovery, doi:10.2174/1570180818666211007111105

https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009840

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Le-Trilling et al., Universally available herbal teas based on sage and perilla elicit potent antiviral activity against SARS-CoV-2 variants of concern by HMOX-1 upregulation in human cells, bioRxiv, doi:10.1101/2020.11.18.388710

https://www.sciencedirect.com/science/article/pii/S2213422021000688

https://www.mdpi.com/2304-8158/10/9/2084/htm

Huang et al., Use of chlorhexidine to eradicate oropharyngeal SARS‐CoV‐2 in COVID‐19 patients, Journal of Medical Virology, doi:10.1002/jmv.26954

Jain et al., Chlorhexidine and SARS-CoV-2 main protease: Molecular docking study, Journal of Indian Society of Periodontology, doi:10.4103/jisp.jisp_39_22

https://www.sciencedirect.com/science/article/pii/S0929664621004691 (Review)

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

https://www.sciencedirect.com/science/article/pii/S0223523421007066

https://www.mdpi.com/2304-8158/10/9/2084/htm

Black, S., Molecular Modeling and Preliminary Clinical Data Suggesting Antiviral Activity for Chlorpheniramine (Chlorphenamine) Against COVID-19, Cureus, doi:10.7759/cureus.20980

Valerio-Pascua et al., Chlorpheniramine Intranasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: The ACCROS Trials, Research Square, doi:10.21203/rs.3.rs-2167465/v1

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Mousavi et al., Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies, Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2022/2044282

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Ke et al., Artificial intelligence approach fighting COVID-19 with repurposing drugs, Biomedical Journal, doi:10.1016/j.bj.2020.05.001

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Kadioglu et al., Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2021.104359

Xu et al., An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges, Biochemical Pharmacology, doi:10.1016/j.bcp.2022.115279

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

Rudrapal et al., Identification of bioactive molecules from Triphala (Ayurvedic herbal formulation) as potential inhibitors of SARS-CoV-2 main protease (Mpro) through computational investigations, Journal of King Saud University - Science, doi:10.1016/j.jksus.2022.101826

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

https://www.sciencedirect.com/science/article/pii/S0223523421007066

https://www.clinicaltherapeutics.com/article/S0149-2918(21)00308-8/fulltext

https://www.sciencedirect.com/science/article/pii/S0006291X21009311

https://www.sciencedirect.com/science/article/pii/S0006291X21013176

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Doshi et al., A computational approach to drug repurposing using graph neural networks, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105992

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Thoene et al., In Vitro Activity of Cysteamine Against SARS-CoV-2 Variants, bioRxiv, doi:10.1101/2021.10.02.462862

Thoene et al., In vitro activity of cysteamine against SARS-CoV-2 variants, Molecular Genetics and Metabolism, doi:10.1016/j.ymgme.2022.08.009

Alonzi et al., Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants, Cell Death Discovery, doi:10.1038/s41420-022-01080-8

Pham et al., A deep learning framework for high-throughput mechanism-driven phenotype compound screening and its application to COVID-19 drug repurposing, Nature Machine Intelligence, doi:10.1038/s42256-020-00285-9

Zhou et al., Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, Cell Discovery, doi:10.1038/s41421-020-0153-3

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

https://www.mdpi.com/2304-8158/10/9/2084/htm

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

https://www.pnas.org/content/118/1/e2021450118 (In Vitro)

https://www.physchemres.org/article_149159.html

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Ali et al., Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2, Archiv der Pharmazie, doi:10.1002/ardp.202100360

https://academic.oup.com/pcm/advance-article/doi/10.1093/pcmedi/pbac024/6713978

Kolev et al., Echinacea purpurea for the Long-term Prevention of Viral Respiratory Tract Infections during COVID-19 Pandemic: A Randomized, Open, Controlled, Exploratory Clinical Study, medRxiv, doi:10.1101/2021.12.10.21267582

Khorshiddoust et al., Efficacy of a multiple-indication antiviral herbal drug (Saliravira®) for COVID-19 outpatients: A pre-clinical and randomized clinical trial study, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.112729

Nicolussi et al., Echinacea as a Potential Force against Coronavirus Infections? A Mini-Review of Randomized Controlled Trials in Adults and Children, Microorganisms, doi:10.3390/microorganisms10020211

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Monserrat Villatoro et al., A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis, Pharmaceuticals, doi:10.3390/ph15010078

https://pubs.asahq.org/anesthesiology/article-abstract/doi/10.1097/ALN.0000000000003999/11..

Ravindran et al., Discovery of host-directed modulators of virus infection by probing the SARS-CoV-2–host protein–protein interaction network, Briefings in Bioinformatics, doi:10.1093/bib/bbac456

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Mirabelli et al., Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2105815118

Ke et al., Artificial intelligence approach fighting COVID-19 with repurposing drugs, Biomedical Journal, doi:10.1016/j.bj.2020.05.001

Sagulkoo et al., Immune-Related Protein Interaction Network in Severe COVID-19 Patients toward the Identification of Key Proteins and Drug Repurposing, Biomolecules, doi:10.3390/biom12050690

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Patel et al., Computational investigation of natural compounds as potential main protease (Mpro) inhibitors for SARS-CoV-2 virus, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106318

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Gordon et al., A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, Nature, doi:10.1038/s41586-020-2286-9

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Doshi et al., A computational approach to drug repurposing using graph neural networks, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105992

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Foster et al., The Use of Hydroxyurea in the Treatment of COVID-19, The Journal of Critical Care Medicine, doi:10.2478/jccm-2021-0019

Sagulkoo et al., Immune-Related Protein Interaction Network in Severe COVID-19 Patients toward the Identification of Key Proteins and Drug Repurposing, Biomolecules, doi:10.3390/biom12050690

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

Shahhamzehei et al., In Silico and In Vitro Identification of Pan-Coronaviral Main Protease Inhibitors from a Large Natural Product Library, Pharmaceuticals, doi:10.3390/ph15030308

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Zhou et al., Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, Cell Discovery, doi:10.1038/s41421-020-0153-3

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Asadi et al., Efficacy of naproxen in the management of patients hospitalized with COVID-19 infection: A randomized, double-blind, placebo-controlled, clinical trial, Diabetes & Metabolic Syndrome: Clinical Research & Reviews, doi:10.1016/j.dsx.2021.102319

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

https://www.mdpi.com/1420-3049/26/9/2593/htm

Ur Rehman et al., Flavonoids and other polyphenols against SARS-CoV-2, Application of Natural Products in SARS-CoV-2, doi:10.1016/B978-0-323-95047-3.00014-9

Aati et al., Garcinia cambogia Phenolics as Potent Anti-COVID-19 Agents: Phytochemical Profiling, Biological Activities, and Molecular Docking, Plants, doi:10.3390/plants11192521

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Eze et al., Anti-COVID-19 Potential of Azadirachta indica (Neem) Leaf Extract, Scientific African, doi:10.1016/j.sciaf.2022.e01184

Srivastava et al., The role of herbal plants in the inhibition of SARS-CoV-2 main protease: A computational approach, Journal of the Indian Chemical Society, doi:10.1016/j.jics.2022.100640

https://pubmed.ncbi.nlm.nih.gov/33891569/ (RCT)

Arshad et al., Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1909

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

https://www.sciencedirect.com/science/article/pii/S0166354222000808

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Patten et al., Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization., iScience, doi:10.1016/j.isci.2022.104925

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

Cho et al., Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19, Scientific Reports, doi:10.1038/s41598-020-72879-7

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Zhou et al., Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, Cell Discovery, doi:10.1038/s41421-020-0153-3

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286244/pdf/main.pdf

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

Ali et al., Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2, Archiv der Pharmazie, doi:10.1002/ardp.202100360

Taquet et al., Exposure to phenytoin associates with a lower risk of post-COVID cognitive deficits: a cohort study, Brain Communications, doi:10.1093/braincomms/fcac206

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Setz et al., Synergistic Antiviral Activity of Pamapimod and Pioglitazone against SARS-CoV-2 and Its Variants of Concern, International Journal of Molecular Sciences, doi:10.3390/ijms23126830

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Yang et al., Potential medicinal plants involved in inhibiting 3CLpro activity: A practical alternate approach to combating COVID-19, Journal of Integrative Medicine, doi:10.1016/j.joim.2022.08.001

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

https://www.sciencedirect.com/science/article/pii/S259009862200029X

Streinu-Cercel et al., Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients with Mild-to-Moderate Coronavirus Disease 2019, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac053

Lee et al., Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score–matched retrospective cohort study, International Immunopharmacology, doi:10.1016/j.intimp.2022.108570

https://pubmed.ncbi.nlm.nih.gov/34724174/

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

Ali et al., Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2, Archiv der Pharmazie, doi:10.1002/ardp.202100360

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Pillaiyar et al., Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy, Journal of Medicinal Chemistry, doi:10.1021/acs.jmedchem.1c00335

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947

Kimura et al., Interim analysis of an open‐label randomized controlled trial evaluating nasal irrigations in non‐hospitalized patients with coronavirus disease 2019, International Forum of Allergy & Rhinology, doi:10.1002/alr.22703

Li et al., Hypertonic saline and aprotinin based blockage of SARS-CoV-2 specific furin site cleavage by inhibition of nasal protease activity, bioRxiv, doi:10.1101/2021.11.19.469276

https://pubmed.ncbi.nlm.nih.gov/33772626/ (Review)

Ju et al., A novel cell culture system modeling the SARS-CoV-2 life cycle, PLOS Pathogens, doi:10.1371/journal.ppat.1009439

Ke et al., Artificial intelligence approach fighting COVID-19 with repurposing drugs, Biomedical Journal, doi:10.1016/j.bj.2020.05.001

Peng et al., Discovery of potential anti-SARS-CoV-2 drugs based on large-scale screening in vitro and effect evaluation in vivo, Science China Life Sciences, doi:10.1007/s11427-021-2031-7

Chellasamy et al., Docking and molecular dynamics studies of human ezrin protein with a modelled SARS-CoV-2 endodomain and their interaction with potential invasion inhibitors, Journal of King Saud University - Science, doi:10.1016/j.jksus.2022.102277

Aminpour et al., In Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds, Computation, doi:10.3390/computation10040051

https://www.biorxiv.org/content/10.1101/2021.04.08.439071v1

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Peng et al., Discovery of potential anti-SARS-CoV-2 drugs based on large-scale screening in vitro and effect evaluation in vivo, Science China Life Sciences, doi:10.1007/s11427-021-2031-7

https://www.mdpi.com/1424-8247/14/3/226

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Pillaiyar et al., Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy, Journal of Medicinal Chemistry, doi:10.1021/acs.jmedchem.1c00335

https://www.senhwabio.com/en/news/20211020

https://trialsitenews.com/senhwa-presents-positive-data-from-phase-2-trial-of-silmitaserti..

Ravindran et al., Discovery of host-directed modulators of virus infection by probing the SARS-CoV-2–host protein–protein interaction network, Briefings in Bioinformatics, doi:10.1093/bib/bbac456

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Pillaiyar et al., Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy, Journal of Medicinal Chemistry, doi:10.1021/acs.jmedchem.1c00335

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Mosharaf et al., Computational identification of host genomic biomarkers highlighting their functions, pathways and regulators that influence SARS-CoV-2 infections and drug repurposing, Scientific Reports, doi:10.1038/s41598-022-08073-8

Sagulkoo et al., Immune-Related Protein Interaction Network in Severe COVID-19 Patients toward the Identification of Key Proteins and Drug Repurposing, Biomolecules, doi:10.3390/biom12050690

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Zhou et al., Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, Cell Discovery, doi:10.1038/s41421-020-0153-3

https://www.biorxiv.org/content/10.1101/2020.04.13.039917v3

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Li et al., Xuanfei Baidu Formula alleviates impaired mitochondrial dynamics and activated NLRP3 inflammasome by repressing NF-κB and MAPK pathways in LPS-induced ALI and inflammation models, Phytomedicine, doi:10.1016/j.phymed.2022.154545

Wu et al., Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China, Frontiers in Pharmacology, doi:10.3389/fphar.2020.615287

https://www.sciencedirect.com/science/article/pii/S2095809921004422

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Dinda et al., Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19, European Journal of Medicinal Chemistry Reports, doi:10.1016/j.ejmcr.2022.100079

Gordon et al., A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, Nature, doi:10.1038/s41586-020-2286-9

Choe et al., The Efficacy of Traditional Medicinal Plants in Modulating the Main Protease of SARS‐CoV‐2 and Cytokine Storm, Chemistry & Biodiversity, doi:10.1002/cbdv.202200655

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

https://www.sciencedirect.com/science/article/pii/S1319562X21007968

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

https://www.sciencedirect.com/science/article/pii/S259009862200029X

Bahadur Gurung et al., An in silico approach unveils the potential of antiviral compounds in preclinical and clinical trials as SARS-CoV-2 Omicron inhibitors, Saudi Journal of Biological Sciences, doi:10.1016/j.sjbs.2022.103297

Pillaiyar et al., Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy, Journal of Medicinal Chemistry, doi:10.1021/acs.jmedchem.1c00335

Kushari et al., An integrated computational approach towards the screening of active plant metabolites as potential inhibitors of SARS-CoV-2: an overview, Structural Chemistry, doi:10.1007/s11224-022-02066-z

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Doshi et al., A computational approach to drug repurposing using graph neural networks, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105992

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Mahoney et al., Antiviral Activity of Aframomum melegueta Against Severe Acute Respiratory Syndrome Coronaviruses type 1 and 2, South African Journal of Botany, doi:10.1016/j.sajb.2021.12.010

Abdallah et al., Bio-Guided Isolation of SARS-CoV-2 Main Protease Inhibitors from Medicinal Plants: In Vitro Assay and Molecular Dynamics, Plants, doi:10.3390/plants11151914

Liu et al., Network Pharmacology and Molecular Docking Elucidate the Underlying Pharmacological Mechanisms of the Herb Houttuynia cordata in Treating Pneumonia Caused by SARS-CoV-2, Viruses, doi:10.3390/v14071588

https://www.mdpi.com/2304-8158/10/9/2084/htm

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

https://www.sciencedirect.com/science/article/abs/pii/S0141813022021432

Nag et al., Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105552

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

Srivastava et al., The role of herbal plants in the inhibition of SARS-CoV-2 main protease: A computational approach, Journal of the Indian Chemical Society, doi:10.1016/j.jics.2022.100640

Hicks et al., Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (Mpro) inhibitors, Bioorganic & Medicinal Chemistry Letters, doi:10.1016/j.bmcl.2022.128732

https://www.cell.com/cell-reports-medicine/pdf/S2666-3791(20)30186-5.pdf

https://www.mdpi.com/1424-8247/14/3/226

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

https://www.mdpi.com/1424-8247/14/3/226

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947

https://www.pnas.org/content/118/1/e2021450118 (In Vitro)

https://www.physchemres.org/article_149159.html

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

https://pubs.asahq.org/anesthesiology/article-abstract/doi/10.1097/ALN.0000000000003999/11..

Ivashchenko et al., Effect of Aprotinin and Avifavir® Combination Therapy for Moderate COVID-19 Patients, Viruses, doi:10.3390/v13071253

Li et al., Hypertonic saline and aprotinin based blockage of SARS-CoV-2 specific furin site cleavage by inhibition of nasal protease activity, bioRxiv, doi:10.1101/2021.11.19.469276

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

https://www.sciencedirect.com/science/article/pii/S0965229921001096

https://osf.io/s3v6k/

Shah et al., In silico studies on therapeutic agents for COVID-19: Drug repurposing approach, Life Sciences, doi:10.1016/j.lfs.2020.117652

Ma et al., Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CLpro, Antiviral Research, doi:10.1016/j.antiviral.2022.105419

Xu et al., An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges, Biochemical Pharmacology, doi:10.1016/j.bcp.2022.115279

Basu et al., Therapeutics for COVID-19 and post COVID-19 complications: An update, Current Research in Pharmacology and Drug Discovery, doi:10.1016/j.crphar.2022.100086

Pham et al., A deep learning framework for high-throughput mechanism-driven phenotype compound screening and its application to COVID-19 drug repurposing, Nature Machine Intelligence, doi:10.1038/s42256-020-00285-9

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Chen et al., The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion, Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.11.022

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Chellasamy et al., Docking and molecular dynamics studies of human ezrin protein with a modelled SARS-CoV-2 endodomain and their interaction with potential invasion inhibitors, Journal of King Saud University - Science, doi:10.1016/j.jksus.2022.102277

Kumar et al., Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection, Virology, doi:10.1016/j.virol.2022.05.004

Zhou et al., Bergamottin, a bioactive component of bergamot, inhibits SARS-CoV-2 infection in golden Syrian hamsters, Antiviral Research, doi:10.1016/j.antiviral.2022.105365

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Mirabelli et al., Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2105815118

Gomaa et al., Boswellic acids/Boswellia serrata extract as a potential COVID-19 therapeutic agent in the elderly, Inflammopharmacology, doi:10.1007/s10787-021-00841-8

Gomaa et al., Advancing combination treatment with glycyrrhizin and boswellic acids for hospitalized patients with moderate COVID-19 infection: a randomized clinical trial, Inflammopharmacology, doi:10.1007/s10787-022-00939-7

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Zhang et al., A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-020-00343-z

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

https://www.biorxiv.org/content/10.1101/2021.08.05.455262v1

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Ao et al., The effect of canakinumab on clinical outcomes in patients with COVID-19: A meta-analysis, Journal of Infection, doi:10.1016/j.jinf.2022.03.011

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Nag et al., Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105552

Abdel-Halim et al., Identification of Drug Combination Therapies for SARS-CoV-2: A Molecular Dynamics Simulations Approach, Drug Design, Development and Therapy, doi:10.2147/DDDT.S366423

Nandi et al., Repurposing of Drugs and HTS to Combat SARS-CoV-2 Main Protease Utilizing Structure-Based Molecular Docking, Letters in Drug Design & Discovery, doi:10.2174/1570180818666211007111105

Doshi et al., A computational approach to drug repurposing using graph neural networks, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105992

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Doshi et al., A computational approach to drug repurposing using graph neural networks, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105992

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Mujwar et al., In silico evaluation of food‐derived carotenoids against SARS‐CoV ‐2 drug targets: Crocin is a promising dietary supplement candidate for COVID ‐19, Journal of Food Biochemistry, doi:10.1111/jfbc.14219

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Zhang et al., A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-020-00343-z

https://www.mdpi.com/2304-8158/10/9/2084/htm

Bhowmick et al., Identification of potent food constituents as SARS-CoV-2 papain-like protease modulators through advanced pharmacoinformatics approaches, Journal of Molecular Graphics and Modelling, doi:10.1016/j.jmgm.2021.108113

https://www.mdpi.com/2304-8158/10/9/2084/htm

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Uhomoibhi et al., Molecular modelling identification of potential drug candidates from selected African plants against SARS-CoV-2 key druggable proteins, Scientific African, doi:10.1016/j.sciaf.2022.e01279

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Uhomoibhi et al., Molecular modelling identification of potential drug candidates from selected African plants against SARS-CoV-2 key druggable proteins, Scientific African, doi:10.1016/j.sciaf.2022.e01279

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Sagulkoo et al., Immune-Related Protein Interaction Network in Severe COVID-19 Patients toward the Identification of Key Proteins and Drug Repurposing, Biomolecules, doi:10.3390/biom12050690

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Chen et al., The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion, Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.11.022

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889471/ (In Vitro)

https://www.mdpi.com/1424-8247/14/3/226

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

Al-Sehemi et al., In Silico Exploration of Binding Potentials of Anti SARS-CoV-1 Phytochemicals against Main Protease of SARS-CoV-2, Journal of Saudi Chemical Society, doi:10.1016/j.jscs.2022.101453

https://www.mdpi.com/2304-8158/10/9/2084/htm

Zhu et al., Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E, Virology, doi:10.1016/j.virol.2022.04.005

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Bhowmick et al., Identification of potent food constituents as SARS-CoV-2 papain-like protease modulators through advanced pharmacoinformatics approaches, Journal of Molecular Graphics and Modelling, doi:10.1016/j.jmgm.2021.108113

Ostrov et al., Highly Specific Sigma Receptor Ligands Exhibit Anti-Viral Properties in SARS-CoV-2 Infected Cells, Pathogens, doi:10.3390/pathogens10111514

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713548/ (Retrospective Study)

Demarest et al., Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19, Antiviral Research, doi:10.1016/j.antiviral.2022.105403

Demarest et al., Brequinar and Dipyridamole in Combination Exhibits Synergistic Antiviral Activity Against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19, bioRxiv, doi:10.1101/2022.03.30.486499

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

https://www.sciencedirect.com/science/article/pii/S1319562X21007968

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

https://con.antppublishing.com/index.php/ittpcovid19/article/view/183

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

Aminpour et al., In Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds, Computation, doi:10.3390/computation10040051

https://www.biorxiv.org/content/10.1101/2021.04.08.439071v1

Rose et al., The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality From COVID-19, Frontiers in Medicine, doi:10.3389/fmed.2021.637647

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009840

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947

https://www.pnas.org/content/118/1/e2021450118ANIMAL:https://www.nature.com/articles/s4146.. (In Vitro)

https://www.physchemres.org/article_149159.html

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Zhou et al., Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, Cell Discovery, doi:10.1038/s41421-020-0153-3

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Kadioglu et al., Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2021.104359

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Bhowmick et al., Identification of potent food constituents as SARS-CoV-2 papain-like protease modulators through advanced pharmacoinformatics approaches, Journal of Molecular Graphics and Modelling, doi:10.1016/j.jmgm.2021.108113

Shimizu et al., LIGHTHOUSE illuminates therapeutics for a variety of diseases including COVID-19, iScience, doi:10.1016/j.isci.2022.105314

https://www.biorxiv.org/content/10.1101/2021.09.25.461785v1

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

https://elifesciences.org/articles/68165

Zhang et al., A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-020-00343-z

https://www.sciencedirect.com/science/article/pii/S2213422021000688

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

https://www.mdpi.com/2304-8158/10/9/2084/htm

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Risner et al., Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture, bioRxiv, doi:10.1101/2020.08.12.246389

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

https://www.physchemres.org/article_149159.html

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Fu et al., Interfering effects on the bioactivities of several key proteins of COVID-19/variants in diabetes by compounds from Lianqiao leaves: In silico and in vitro analyses, International Journal of Biological Macromolecules, doi:10.1016/j.ijbiomac.2022.03.145

https://www.sciencedirect.com/science/article/pii/S0223523421007066

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

Srivastava et al., The role of herbal plants in the inhibition of SARS-CoV-2 main protease: A computational approach, Journal of the Indian Chemical Society, doi:10.1016/j.jics.2022.100640

https://www.jcchems.com/index.php/JCCHEMS/article/download/1802/561

Basu et al., Therapeutics for COVID-19 and post COVID-19 complications: An update, Current Research in Pharmacology and Drug Discovery, doi:10.1016/j.crphar.2022.100086

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Li, C., Can Glycine Mitigate COVID-19 Associated Tissue Damage and Cytokine Storm?, Radiation Research, doi:10.1667/RADE-20-00146.1

Kumar et al., Severe Glutathione Deficiency, Oxidative Stress and Oxidant Damage in Adults Hospitalized with COVID-19: Implications for GlyNAC (Glycine and N-Acetylcysteine) Supplementation, Antioxidants, doi:10.3390/antiox11010050

Ma et al., Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CLpro, Antiviral Research, doi:10.1016/j.antiviral.2022.105419

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Mousavi et al., Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies, Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2022/2044282

https://pubmed.ncbi.nlm.nih.gov/34375189/ (In Vitro)

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

https://www.mdpi.com/1660-3397/19/8/418

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Bhowmick et al., Identification of bio-active food compounds as potential SARS-CoV-2 PLpro inhibitors-modulators via negative image-based screening and computational simulations, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105474

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Mousavi et al., Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies, Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2022/2044282

https://www.sciencedirect.com/science/article/abs/pii/S1386142521011720

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Wu et al., Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China, Frontiers in Pharmacology, doi:10.3389/fphar.2020.615287

https://www.sciencedirect.com/science/article/abs/pii/S0944711321004086

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Alamgir et al., Drug repositioning candidates identified using in-silico quasi-quantum molecular simulation demonstrate reduced COVID-19 mortality in 1.5M patient records, medRxiv, doi:10.1101/2021.03.22.21254110

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Azeem et al., Virtual screening of phytochemicals by targeting multiple proteins of severe acute respiratory syndrome coronavirus 2: Molecular docking and molecular dynamics simulation studies, International Journal of Immunopathology and Pharmacology, doi:10.1177/03946320221142793

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Yang et al., Potential medicinal plants involved in inhibiting 3CLpro activity: A practical alternate approach to combating COVID-19, Journal of Integrative Medicine, doi:10.1016/j.joim.2022.08.001

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

Basu et al., Therapeutics for COVID-19 and post COVID-19 complications: An update, Current Research in Pharmacology and Drug Discovery, doi:10.1016/j.crphar.2022.100086

Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Monserrat Villatoro et al., A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis, Pharmaceuticals, doi:10.3390/ph15010078

Mirabelli et al., Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2105815118

Zhou et al., Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, Cell Discovery, doi:10.1038/s41421-020-0153-3

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Lu et al., Jing Si Herbal Drink as a Prospective Adjunctive Therapy for COVID-19 Treatment: Molecular evidence and mechanisms, Pharmacological Research - Modern Chinese Medicine, doi:10.1016/j.prmcm.2021.100024

Hsieh et al., Efficacy and Safety of Complementary Therapy With Jing Si Herbal Tea in Patients With Mild-To-Moderate COVID-19: A Prospective Cohort Study, Frontiers in Nutrition, doi:10.3389/fnut.2022.832321

Wu et al., Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China, Frontiers in Pharmacology, doi:10.3389/fphar.2020.615287

https://www.medrxiv.org/content/10.1101/2022.05.16.22275074v1

https://www.trialsitenews.com/p/trialsitenews/novel-chinese-oral-covid-19-treatment-begins..

https://www1.hkexnews.hk/listedco/listconews/sehk/2022/0524/2022052301170.pdf

Izzo et al., Combining L-Arginine with Vitamin C Improves Long-COVID Symptoms: The Nationwide Multicenter LINCOLN Study, Pharmacological Research, doi:10.1016/j.phrs.2022.106360

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00405-3/fulltext (RCT)

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Medhat et al., Sofosbuvir/Ledipasvir in Combination or Nitazoxanide Alone are Safe and Efficient Treatments for COVID-19 Infection: A Randomized Controlled Trial for Repurposing antivirals, Arab Journal of Gastroenterology, doi:10.1016/j.ajg.2022.04.005

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00494-X/fulltext

Basu et al., Therapeutics for COVID-19 and post COVID-19 complications: An update, Current Research in Pharmacology and Drug Discovery, doi:10.1016/j.crphar.2022.100086

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Liu et al., Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus, Bioinformatics, doi:10.1093/bioinformatics/btaa224

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Xia et al., Network pharmacology and molecular docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID‐19, Cell Proliferation, doi:10.1111/cpr.12949

Wu et al., Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China, Frontiers in Pharmacology, doi:10.3389/fphar.2020.615287

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Sharma et al., Nutraceuticals aid in managing COVID-19, World Journal of Pharmaceutical Sciences, doi:10.54037/WJPS.2022.100204

https://www.researchgate.net/profile/Ravi-Patel-57/publication/362712299_Liquiritin_from_G..

Chen et al., The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion, Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.11.022

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Pillaiyar et al., Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy, Journal of Medicinal Chemistry, doi:10.1021/acs.jmedchem.1c00335

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

Xu et al., An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges, Biochemical Pharmacology, doi:10.1016/j.bcp.2022.115279

Zhang et al., A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-020-00343-z

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

Risner et al., Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture, bioRxiv, doi:10.1101/2020.08.12.246389

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Ravindran et al., Discovery of host-directed modulators of virus infection by probing the SARS-CoV-2–host protein–protein interaction network, Briefings in Bioinformatics, doi:10.1093/bib/bbac456

Arshad et al., Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1909

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Mirabelli et al., Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2105815118

Mody et al., Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents, Communications Biology, doi:10.1038/s42003-020-01577-x

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Chellasamy et al., Docking and molecular dynamics studies of human ezrin protein with a modelled SARS-CoV-2 endodomain and their interaction with potential invasion inhibitors, Journal of King Saud University - Science, doi:10.1016/j.jksus.2022.102277

https://www.sciencedirect.com/science/article/pii/S259009862200029X

Sagulkoo et al., Immune-Related Protein Interaction Network in Severe COVID-19 Patients toward the Identification of Key Proteins and Drug Repurposing, Biomolecules, doi:10.3390/biom12050690

https://www.sciencedirect.com/science/article/pii/S259009862200029X

Luedemann et al., Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing, Computational and Structural Biotechnology Journal, doi:10.1016/j.csbj.2022.01.024

Kerget et al., Effect of montelukast therapy on clinical course, pulmonary function, and mortality in patients with COVID‐19, Journal of Medical Virology, doi:10.1002/jmv.27552

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Chellasamy et al., Docking and molecular dynamics studies of human ezrin protein with a modelled SARS-CoV-2 endodomain and their interaction with potential invasion inhibitors, Journal of King Saud University - Science, doi:10.1016/j.jksus.2022.102277

Aminpour et al., In Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds, Computation, doi:10.3390/computation10040051

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Aminpour et al., In Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds, Computation, doi:10.3390/computation10040051

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Kanchibhotla et al., Rate of Recovery and Symptomatic Efficacy of a Polyherbal AYUSH Formulation in the Treatment of SARS CoV-2 disease: A Single-arm trial, Research Square, doi:10.21203/rs.3.rs-923003/v4

Bhardwaja et al., An integrative approach to clinical recovery for COVID-19 patients using an Ayurvedic formulation: A multicentric double-blind randomized control trial., Research Square, doi:10.21203/rs.3.rs-1165680/v1

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Wei et al., Targeting spike protein-induced TLR/NET axis by COVID-19 therapeutic NRICM102 ameliorates pulmonary embolism and fibrosis, Pharmacological Research, doi:10.1016/j.phrs.2022.106424

Tseng et al., Curbing COVID-19 progression and mortality with traditional Chinese medicine among hospitalized patients with COVID-19: A propensity score-matched analysis, Pharmacological Research, doi:10.1016/j.phrs.2022.106412

Aminpour et al., In Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds, Computation, doi:10.3390/computation10040051

Kadioglu et al., Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2021.104359

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Mody et al., Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents, Communications Biology, doi:10.1038/s42003-020-01577-x

Wang et al., Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture, Communications Biology, doi:10.1038/s42003-022-03101-9

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Jang et al., Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2024302118

Pillaiyar et al., Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy, Journal of Medicinal Chemistry, doi:10.1021/acs.jmedchem.1c00335

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Ravindran et al., Discovery of host-directed modulators of virus infection by probing the SARS-CoV-2–host protein–protein interaction network, Briefings in Bioinformatics, doi:10.1093/bib/bbac456

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Pillaiyar et al., Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy, Journal of Medicinal Chemistry, doi:10.1021/acs.jmedchem.1c00335

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009840

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7883493/

https://pubmed.ncbi.nlm.nih.gov/32526061/

Pham et al., A deep learning framework for high-throughput mechanism-driven phenotype compound screening and its application to COVID-19 drug repurposing, Nature Machine Intelligence, doi:10.1038/s42256-020-00285-9

Wang et al., Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture, Communications Biology, doi:10.1038/s42003-022-03101-9

Liu et al., Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus, Bioinformatics, doi:10.1093/bioinformatics/btaa224

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Nag et al., Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105552

https://www.jcchems.com/index.php/JCCHEMS/article/download/1802/561

dos Reis et al., Effects of bioactive compounds from Pleurotus mushrooms on COVID-19 risk factors associated with the cardiovascular system, Journal of Integrative Medicine, doi:10.1016/j.joim.2022.07.002

Elhusseiny et al., In vitro Anti SARS-CoV-2 Activity and Docking Analysis of Pleurotus ostreatus, Lentinula edodes and Agaricus bisporus Edible Mushrooms, Infection and Drug Resistance, doi:10.2147/IDR.S362823

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Kadioglu et al., Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2021.104359

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Gordon et al., A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, Nature, doi:10.1038/s41586-020-2286-9

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Zhang et al., A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-020-00343-z

https://www.mdpi.com/2304-8158/10/9/2084/htm

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Uhomoibhi et al., Molecular modelling identification of potential drug candidates from selected African plants against SARS-CoV-2 key druggable proteins, Scientific African, doi:10.1016/j.sciaf.2022.e01279

https://www.mdpi.com/2304-8158/10/9/2084/htm

Azeem et al., Virtual screening of phytochemicals by targeting multiple proteins of severe acute respiratory syndrome coronavirus 2: Molecular docking and molecular dynamics simulation studies, International Journal of Immunopathology and Pharmacology, doi:10.1177/03946320221142793

Ur Rehman et al., Flavonoids and other polyphenols against SARS-CoV-2, Application of Natural Products in SARS-CoV-2, doi:10.1016/B978-0-323-95047-3.00014-9

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Beck et al., Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model, Computational and Structural Biotechnology Journal, doi:10.1016/j.csbj.2020.03.025

Mosharaf et al., Computational identification of host genomic biomarkers highlighting their functions, pathways and regulators that influence SARS-CoV-2 infections and drug repurposing, Scientific Reports, doi:10.1038/s41598-022-08073-8

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Zhang et al., A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-020-00343-z

https://digitalcommons.pcom.edu/research_day/research_day_GA_2022/researchGA2022/20/

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Khorshiddoust et al., Efficacy of a multiple-indication antiviral herbal drug (Saliravira®) for COVID-19 outpatients: A pre-clinical and randomized clinical trial study, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.112729

https://www.sciencedirect.com/science/article/pii/S2213422021000688

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Sasaki et al., Oral administration of S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and accelerates recovery from clinical aspects of COVID-19, bioRxiv, doi:10.1101/2022.02.14.480338

https://www.thepharmaletter.com/article/shionogi-progressing-covid-19-oral-antiviral-agent..

Barnette et al., Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis, NEJM Evidence, doi:10.1056/EVIDoa2200145

https://www.trialsitenews.com/p/trialsitenews/safety-monitoring-board-stops-clinical-trial..

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Pillaiyar et al., Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy, Journal of Medicinal Chemistry, doi:10.1021/acs.jmedchem.1c00335

Yin et al., Computational Screening of Repurposed Drugs Targeting Sars-Cov-2 Main Protease By Molecular Docking, Sudan Journal of Medical Sciences, doi:10.18502/sjms.v17i3.12125

http://journal.oiu.edu.sd/index.php/FMHS/article/view/2688

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

https://www.mdpi.com/2304-8158/10/9/2084/htm

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Azeem et al., Virtual screening of phytochemicals by targeting multiple proteins of severe acute respiratory syndrome coronavirus 2: Molecular docking and molecular dynamics simulation studies, International Journal of Immunopathology and Pharmacology, doi:10.1177/03946320221142793

Dinda et al., Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19, European Journal of Medicinal Chemistry Reports, doi:10.1016/j.ejmcr.2022.100079

Al-Sehemi et al., In Silico Exploration of Binding Potentials of Anti SARS-CoV-1 Phytochemicals against Main Protease of SARS-CoV-2, Journal of Saudi Chemical Society, doi:10.1016/j.jscs.2022.101453

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

https://www.medrxiv.org/content/10.1101/2022.01.21.22269322v1

Srivastava et al., The role of herbal plants in the inhibition of SARS-CoV-2 main protease: A computational approach, Journal of the Indian Chemical Society, doi:10.1016/j.jics.2022.100640

https://www.jcchems.com/index.php/JCCHEMS/article/download/1802/561

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Pillaiyar et al., Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy, Journal of Medicinal Chemistry, doi:10.1021/acs.jmedchem.1c00335

Chen et al., Tafenoquine and its derivatives as inhibitors for the Severe Acute Respiratory Syndrome Coronavirus 2, Journal of Biological Chemistry, doi:10.1016/j.jbc.2022.101658

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Xu et al., An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges, Biochemical Pharmacology, doi:10.1016/j.bcp.2022.115279

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Chellasamy et al., Docking and molecular dynamics studies of human ezrin protein with a modelled SARS-CoV-2 endodomain and their interaction with potential invasion inhibitors, Journal of King Saud University - Science, doi:10.1016/j.jksus.2022.102277

Abdallah et al., Bio-Guided Isolation of SARS-CoV-2 Main Protease Inhibitors from Medicinal Plants: In Vitro Assay and Molecular Dynamics, Plants, doi:10.3390/plants11151914

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Pillaiyar et al., Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy, Journal of Medicinal Chemistry, doi:10.1021/acs.jmedchem.1c00335

Yang et al., Potential medicinal plants involved in inhibiting 3CLpro activity: A practical alternate approach to combating COVID-19, Journal of Integrative Medicine, doi:10.1016/j.joim.2022.08.001

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

Mody et al., Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents, Communications Biology, doi:10.1038/s42003-020-01577-x

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Basu et al., Therapeutics for COVID-19 and post COVID-19 complications: An update, Current Research in Pharmacology and Drug Discovery, doi:10.1016/j.crphar.2022.100086

Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947

Polanco et al., Caracterización del uso de tofacitinib como tratamiento para covid-19, Revista Colombiana de Reumatología, doi:10.1016/j.rcreu.2022.03.002

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

https://trialsitenews.com/todos-medicals-antiviral-treatment-tollovir-reduces-covid-19-mor..

https://academic.oup.com/pcm/advance-article/doi/10.1093/pcmedi/pbac024/6713978

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

https://www.sciencedirect.com/science/article/abs/pii/S1576988722001893

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Riva et al., A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals, bioRxiv, doi:10.1101/2020.04.16.044016

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Mirabelli et al., Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2105815118

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Barberis et al., Understanding protection from SARS-CoV-2 using metabolomics, Scientific Reports, doi:10.1038/s41598-021-93260-2

Angeles-Agdeppa et al., Virgin coconut oil is effective in lowering C-reactive protein levels among suspect and probable cases of COVID-19, Journal of Functional Foods, doi:10.1016/j.jff.2021.104557

Chen et al., The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion, Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.11.022

Pandya et al., Unravelling Vitamin B12 as a potential inhibitor against SARS-CoV-2: A computational approach, Informatics in Medicine Unlocked, doi:10.1016/j.imu.2022.100951

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Choe et al., The Efficacy of Traditional Medicinal Plants in Modulating the Main Protease of SARS‐CoV‐2 and Cytokine Storm, Chemistry & Biodiversity, doi:10.1002/cbdv.202200655

http://www.ichp.vot.pl/index.php/p/article/view/1148

Choe et al., The Efficacy of Traditional Medicinal Plants in Modulating the Main Protease of SARS‐CoV‐2 and Cytokine Storm, Chemistry & Biodiversity, doi:10.1002/cbdv.202200655

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Yang et al., Potential medicinal plants involved in inhibiting 3CLpro activity: A practical alternate approach to combating COVID-19, Journal of Integrative Medicine, doi:10.1016/j.joim.2022.08.001

https://www.mdpi.com/2304-8158/10/9/2084/htm

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

Mirabelli et al., Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2105815118

Kladnik et al., Zinc pyrithione is a potent inhibitor of PLPro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication, bioRxiv, doi:10.1101/2022.03.03.482819

Kladnik et al., Zinc pyrithione is a potent inhibitor of PL^Pro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication, Journal of Enzyme Inhibition and Medicinal Chemistry, doi:10.1080/14756366.2022.2108417

Askari et al., Digging for the Discovery of SARS-CoV-2 nsp12 Inhibitors: A Pharmacophore-Based and Molecular Dynamics Simulation Study, Research Square, doi:10.21203/rs.3.rs-907714/v1

Askari et al., Digging for the discovery of SARS-CoV-2 nsp12 inhibitors: a pharmacophore-based and molecular dynamics simulation study, Future Virology, doi:10.2217/fvl-2022-0054

Liu et al., Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus, Bioinformatics, doi:10.1093/bioinformatics/btaa224

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

Yu et al., Identification and Semisynthesis of (−)-Anisomelic Acid as Oral Agent against SARS-CoV-2 in Mice, National Science Review, doi:10.1093/nsr/nwac176

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

Kumar et al., Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection, Virology, doi:10.1016/j.virol.2022.05.004

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Ali et al., Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2, Archiv der Pharmazie, doi:10.1002/ardp.202100360

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Ali et al., Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2, Archiv der Pharmazie, doi:10.1002/ardp.202100360

https://www.sciencedirect.com/science/article/pii/S2352914822002714

Kadioglu et al., Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2021.104359

Bruchelt et al., Proposal for the use of an inhalation drug containing 2-5 oligoadenylates for treatment of COVID-19, Medical Hypotheses, doi:10.1016/j.mehy.2022.110969

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Basu et al., Therapeutics for COVID-19 and post COVID-19 complications: An update, Current Research in Pharmacology and Drug Discovery, doi:10.1016/j.crphar.2022.100086

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Khanal et al., Computational investigation of benzalacetophenone derivatives against SARS-CoV-2 as potential multi-target bioactive compounds, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105668

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Yang et al., Potential medicinal plants involved in inhibiting 3CLpro activity: A practical alternate approach to combating COVID-19, Journal of Integrative Medicine, doi:10.1016/j.joim.2022.08.001

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

https://www.mdpi.com/2304-8158/10/9/2084/htm

https://www.liebertpub.com/doi/10.1089/dna.2022.0312

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Khanal et al., Computational investigation of benzalacetophenone derivatives against SARS-CoV-2 as potential multi-target bioactive compounds, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105668

Byadi et al., In silico discovery of novel inhibitors from Northern African natural products database against main protease (Mpro) of SARS-CoV-2, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2022.2040594

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Abdallah et al., Bio-Guided Isolation of SARS-CoV-2 Main Protease Inhibitors from Medicinal Plants: In Vitro Assay and Molecular Dynamics, Plants, doi:10.3390/plants11151914

Serra et al., Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation, Briefings in Bioinformatics, doi:10.1093/bib/bbab507

https://www.biorxiv.org/content/10.1101/2021.06.04.447066v2

https://www.sciencedirect.com/science/article/pii/S2352914822002714

Ma et al., Efficient Neutralization of SARS-CoV-2 Omicron and Other VOCs by a Broad Spectrum Antibody 8G3, bioRxiv, doi:10.1101/2022.02.25.482049

Patten et al., Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization., iScience, doi:10.1016/j.isci.2022.104925

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Sim et al., Amelioration of SARS-CoV-2 infection by ANO6 phospholipid scramblase inhibition, Cell Reports, doi:10.1016/j.celrep.2022.111117

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Basu et al., Therapeutics for COVID-19 and post COVID-19 complications: An update, Current Research in Pharmacology and Drug Discovery, doi:10.1016/j.crphar.2022.100086

Uhomoibhi et al., Molecular modelling identification of potential drug candidates from selected African plants against SARS-CoV-2 key druggable proteins, Scientific African, doi:10.1016/j.sciaf.2022.e01279

Shah et al., In silico studies on therapeutic agents for COVID-19: Drug repurposing approach, Life Sciences, doi:10.1016/j.lfs.2020.117652

Ali et al., Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2, Archiv der Pharmazie, doi:10.1002/ardp.202100360

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Li et al., Inpatient Use of Metformin and Acarbose Is Associated with Reduced Mortality of COVID-19 Patients with Type 2 Diabetes Mellitus, Research Square, doi:10.21203/rs.3.rs-287308/v1

Britton et al., Engineered Multivalent Self-Assembled Binder Protein Against SARS-CoV-2 RBD, Biochemical Engineering Journal, doi:10.1016/j.bej.2022.108596

Cohen-Dvashi et al., Anti-SARS-CoV-2 immunoadhesin remains effective against Omicron and other emerging variants of concern, iScience, doi:10.1016/j.isci.2022.105193

Li et al., Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2, Computational and Structural Biotechnology Journal, doi:10.1016/j.csbj.2020.08.016

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Fàbrega-Ferrer et al., Structure and inhibition of SARS-CoV-1 and SARS-CoV-2 main proteases by oral antiviral compound AG7404, Antiviral Research, doi:10.1016/j.antiviral.2022.105458

Elhusseiny et al., In vitro Anti SARS-CoV-2 Activity and Docking Analysis of Pleurotus ostreatus, Lentinula edodes and Agaricus bisporus Edible Mushrooms, Infection and Drug Resistance, doi:10.2147/IDR.S362823

Cecon et al., Melatonin drugs inhibit SARS-CoV-2 entry into the brain and virus-induced damage of cerebral small vessels, bioRxiv, doi:10.1101/2021.12.30.474561

Veerasamy et al., Molecular docking unveils the potential of andrographolide derivatives against COVID-19: an in silico approach, Journal of Genetic Engineering and Biotechnology, doi:10.1186/s43141-022-00339-y

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Zhang et al., A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-020-00343-z

https://www.mdpi.com/1420-3049/27/16/5174

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

Srivastava et al., The role of herbal plants in the inhibition of SARS-CoV-2 main protease: A computational approach, Journal of the Indian Chemical Society, doi:10.1016/j.jics.2022.100640

Hicks et al., Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (Mpro) inhibitors, Bioorganic & Medicinal Chemistry Letters, doi:10.1016/j.bmcl.2022.128732

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Chen et al., The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion, Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.11.022

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

http://ao.um5.ac.ma/xmlui/handle/123456789/20002

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Pham et al., A deep learning framework for high-throughput mechanism-driven phenotype compound screening and its application to COVID-19 drug repurposing, Nature Machine Intelligence, doi:10.1038/s42256-020-00285-9

https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009840

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

Alamgir et al., Drug repositioning candidates identified using in-silico quasi-quantum molecular simulation demonstrate reduced COVID-19 mortality in 1.5M patient records, medRxiv, doi:10.1101/2021.03.22.21254110

Aminpour et al., In Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds, Computation, doi:10.3390/computation10040051

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Babu et al., Identification of differentially expressed genes and their major pathways among the patient with COVID-19, cystic fibrosis, and chronic kidney disease, Informatics in Medicine Unlocked, doi:10.1016/j.imu.2022.101038

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

Hicks et al., Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (Mpro) inhibitors, Bioorganic & Medicinal Chemistry Letters, doi:10.1016/j.bmcl.2022.128732

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Arshad et al., Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1909

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Patten et al., Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization., iScience, doi:10.1016/j.isci.2022.104925

Sayed et al., Microbial Natural Products as Potential Inhibitors of SARS-CoV-2 Main Protease (Mpro), Microorganisms, doi:10.3390/microorganisms8070970

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Adem et al., Multidimensional in silico strategy for identification of natural polyphenols-based SARS-CoV-2 main protease (Mpro) inhibitors to unveil a hope against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105452

Dinda et al., Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19, European Journal of Medicinal Chemistry Reports, doi:10.1016/j.ejmcr.2022.100079

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Arshad et al., Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1909

Patten et al., Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization., iScience, doi:10.1016/j.isci.2022.104925

Chen et al., The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion, Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.11.022

https://www.pnas.org/content/118/1/e2021450118 (In Vitro)

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

https://www.degruyter.com/document/doi/10.1515/jcim-2021-0241/html (In Silico)

Pillaiyar et al., Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy, Journal of Medicinal Chemistry, doi:10.1021/acs.jmedchem.1c00335

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

Basu et al., Therapeutics for COVID-19 and post COVID-19 complications: An update, Current Research in Pharmacology and Drug Discovery, doi:10.1016/j.crphar.2022.100086

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Abu-Melha et al., Potential COVID-19 Drug Candidates Based on Diazinyl-Thiazol-Imine Moieties: Synthesis and Greener Pastures Biological Study, Molecules, doi:10.3390/molecules27020488

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

https://academic.oup.com/pcm/advance-article/doi/10.1093/pcmedi/pbac024/6713978

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Haritha et al., Quantum chemical studies on the binding domain of SARS-CoV-2 S-protein: human ACE2 interface complex, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2022.2120537

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Laplantine et al., The FDA-approved drug Auranofin has a dual inhibitory effect on SARS-CoV-2 entry and NF-κB signaling, iScience, doi:10.1016/j.isci.2022.105066

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Mukherjee et al., Anticipated pharmacological role of Aviptadil on COVID-19, Environmental Science and Pollution Research, doi:10.1007/s11356-021-17824-5

https://journals.asm.org/doi/10.1128/spectrum.03331-22

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Sankhe et al., A Randomized, Controlled, Blinded, Parallel Group, Clinical Trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India., Complementary Therapies in Medicine, doi:10.1016/j.ctim.2022.102824

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Serra et al., Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation, Briefings in Bioinformatics, doi:10.1093/bib/bbab507

Patten et al., Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization., iScience, doi:10.1016/j.isci.2022.104925

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

https://www.sciencedirect.com/science/article/pii/S259009862200029X

Kar et al., Identification of phytocompounds as newer antiviral drugs against COVID-19 through molecular docking and simulation based study, Journal of Molecular Graphics and Modelling, doi:10.1016/j.jmgm.2022.108192

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Zhang et al., A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-020-00343-z

Patten et al., Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization., iScience, doi:10.1016/j.isci.2022.104925

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Pasquero et al., Novel antiviral activity of PAD inhibitors against human beta-coronaviruses HCoV-OC43 and SARS-CoV-2, Antiviral Research, doi:10.1016/j.antiviral.2022.105278

Al Khoury et al., In silico evidence of beauvericin antiviral activity against SARS-CoV-2, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2021.105171

Talluri, S., Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19, Combinatorial Chemistry & High Throughput Screening, doi:10.2174/1386207323666200814132149

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Monserrat Villatoro et al., A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis, Pharmaceuticals, doi:10.3390/ph15010078

https://academic.oup.com/pcm/advance-article/doi/10.1093/pcmedi/pbac024/6713978

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Haritha et al., Quantum chemical studies on the binding domain of SARS-CoV-2 S-protein: human ACE2 interface complex, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2022.2120537

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

https://www.mdpi.com/2304-8158/10/9/2084/htm

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Mousavi et al., Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies, Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2022/2044282

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

Aminpour et al., In Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds, Computation, doi:10.3390/computation10040051

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Azeem et al., Virtual screening of phytochemicals by targeting multiple proteins of severe acute respiratory syndrome coronavirus 2: Molecular docking and molecular dynamics simulation studies, International Journal of Immunopathology and Pharmacology, doi:10.1177/03946320221142793

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

https://www.physchemres.org/article_149159.html

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

Taha et al., Identification of FDA-approved Bifonazole as SARS-CoV-2 blocking agent following a bioreporter drug screen, Molecular Therapy, doi:10.1016/j.ymthe.2022.04.025

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

https://www.mdpi.com/2304-8158/10/9/2084/htm

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Said et al., Synthesis and Greener Pastures Biological Study of Bis-thiadiazoles as Potential Covid-19 Drug Candidates, Arabian Journal of Chemistry, doi:10.1016/j.arabjc.2022.104101

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Beth Yacyshyn et al., Feasibility study of Bismuth Subsalicylate (BSS) as an addition to standard of care for COVID-19 therapy, Current Therapeutic Research, doi:10.1016/j.curtheres.2022.100667

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Patten et al., Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization., iScience, doi:10.1016/j.isci.2022.104925

Bijelić et al., Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence, Antibiotics, doi:10.3390/antibiotics11111614

Basu et al., Therapeutics for COVID-19 and post COVID-19 complications: An update, Current Research in Pharmacology and Drug Discovery, doi:10.1016/j.crphar.2022.100086

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Jang et al., Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2024302118

Kocher et al., Visible blue light inactivates SARS-CoV-2 variants and inhibits Delta replication in differentiated human airway epithelia, bioRxiv, doi:10.1101/2022.01.25.477616

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

Akbari et al., Possible therapeutic effects of boron citrate and oleoylethanolamide supplementation in patients with COVID-19: A pilot randomized, double-blind, clinical trial, Journal of Trace Elements in Medicine and Biology, doi:10.1016/j.jtemb.2022.126945

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0253489

Kader et al., Effects of short-term breathing exercises on respiratory recovery in patients with COVID-19: a quasi-experimental study, BMC Sports Science, Medicine and Rehabilitation, doi:10.1186/s13102-022-00451-z

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

https://trialsitenews.com/brii-bio-initiates-submission-of-emergency-use-authorization-fil..

Basu et al., Therapeutics for COVID-19 and post COVID-19 complications: An update, Current Research in Pharmacology and Drug Discovery, doi:10.1016/j.crphar.2022.100086

https://www.sciencedirect.com/science/article/pii/S2589936820300463?via%3Dihub

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Al-Sehemi et al., In Silico Exploration of Binding Potentials of Anti SARS-CoV-1 Phytochemicals against Main Protease of SARS-CoV-2, Journal of Saudi Chemical Society, doi:10.1016/j.jscs.2022.101453

Patten et al., Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization., iScience, doi:10.1016/j.isci.2022.104925

Zhang et al., A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-020-00343-z

https://clinicaltrials.gov/ct2/show/NCT04504734

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Zhang et al., A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-020-00343-z

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

https://www.sciencedirect.com/science/article/pii/S2352914822002714

Basu et al., Therapeutics for COVID-19 and post COVID-19 complications: An update, Current Research in Pharmacology and Drug Discovery, doi:10.1016/j.crphar.2022.100086

Jain et al., RNASeq profiling of COVID19‐infected patients identified an EIF2AK2 inhibitor as a potent SARS‐CoV‐2 antiviral, Clinical and Translational Medicine, doi:10.1002/ctm2.1098

https://www.nature.com/articles/s41598-021-97268-6

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

Leka et al., In vitro antiviral activity against SARS‐CoV ‐2 of common herbal medicinal extracts and their bioactive compounds, Phytotherapy Research, doi:10.1002/ptr.7463

Zhou et al., Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, Cell Discovery, doi:10.1038/s41421-020-0153-3

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Lazniewski et al., Drug repurposing for identification of potential spike inhibitors for SARS-CoV-2 using molecular docking and molecular dynamics simulations, Methods, doi:10.1016/j.ymeth.2022.02.004

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

https://www.mdpi.com/1420-3049/27/18/6127

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Basu et al., Therapeutics for COVID-19 and post COVID-19 complications: An update, Current Research in Pharmacology and Drug Discovery, doi:10.1016/j.crphar.2022.100086

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Liu et al., Identification of SARS-CoV-2 Main Protease Inhibitors from a Library of Minor Cannabinoids by Biochemical Inhibition Assay and Surface Plasmon Resonance Characterized Binding Affinity, Molecules, doi:10.3390/molecules27186127

Welker et al., Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study, The Lancet Infectious Diseases, doi:10.1016/S1473-3099(22)00058-5

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Nandi et al., Repurposing of Drugs and HTS to Combat SARS-CoV-2 Main Protease Utilizing Structure-Based Molecular Docking, Letters in Drug Design & Discovery, doi:10.2174/1570180818666211007111105

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Monserrat Villatoro et al., A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis, Pharmaceuticals, doi:10.3390/ph15010078

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Yang et al., Potential medicinal plants involved in inhibiting 3CLpro activity: A practical alternate approach to combating COVID-19, Journal of Integrative Medicine, doi:10.1016/j.joim.2022.08.001

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Shah et al., In silico studies on therapeutic agents for COVID-19: Drug repurposing approach, Life Sciences, doi:10.1016/j.lfs.2020.117652

Rudrapal et al., Identification of bioactive molecules from Triphala (Ayurvedic herbal formulation) as potential inhibitors of SARS-CoV-2 main protease (Mpro) through computational investigations, Journal of King Saud University - Science, doi:10.1016/j.jksus.2022.101826

Faisal et al., Identification and Inhibition of the Druggable Allosteric Site of SARS-CoV-2 NSP10/NSP16 Methyltransferase through Computational Approaches, Molecules, doi:10.3390/molecules27165241

Mortezaei et al., Variations of SARS-CoV-2 in the Iranian Population and Candidate Putative Drug-like Compounds to Inhibit the Mutated Proteins, Heliyon, doi:10.1016/j.heliyon.2022.e09910

Alonso et al., A Retrospective Observational Study of Chlorine Dioxide Effectiveness to Covid19-like Symptoms Prophylaxis in Relatives Living with COVID19 Patients, International Journal of Multidisciplinary Research and Analysis, doi:10.47191/ijmra/v4-i8-02

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Youn et al., Robust therapeutic effects on COVID-19 of novel small molecules: Alleviation of SARS-CoV-2 S protein induction of ACE2/TMPRSS2, NOX2/ROS, and MCP-1, Frontiers in Cardiovascular Medicine, doi:10.3389/fcvm.2022.957340

Kushari et al., An integrated computational approach towards the screening of active plant metabolites as potential inhibitors of SARS-CoV-2: an overview, Structural Chemistry, doi:10.1007/s11224-022-02066-z

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8291116/

Pillaiyar et al., Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy, Journal of Medicinal Chemistry, doi:10.1021/acs.jmedchem.1c00335

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Nag et al., Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105552

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

Zhang et al., A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-020-00343-z

Nandi et al., Repurposing of Drugs and HTS to Combat SARS-CoV-2 Main Protease Utilizing Structure-Based Molecular Docking, Letters in Drug Design & Discovery, doi:10.2174/1570180818666211007111105

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Sayed et al., Microbial Natural Products as Potential Inhibitors of SARS-CoV-2 Main Protease (Mpro), Microorganisms, doi:10.3390/microorganisms8070970

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Liu et al., Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus, Bioinformatics, doi:10.1093/bioinformatics/btaa224

Pasquero et al., Novel antiviral activity of PAD inhibitors against human beta-coronaviruses HCoV-OC43 and SARS-CoV-2, Antiviral Research, doi:10.1016/j.antiviral.2022.105278

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Gordon et al., A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, Nature, doi:10.1038/s41586-020-2286-9

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

Song et al., Oral antiviral clevudine compared with placebo in Korean COVID-19 patients with moderate severity, medRxiv, doi:10.1101/2021.12.09.21267566

https://www.wjpr.net/abstract_show/19601

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Belouzard et al., Clofoctol inhibits SARS-CoV-2 replication and reduces lung pathology in mice, bioRxiv, doi:10.1101/2021.06.30.450483

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Gordon et al., A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, Nature, doi:10.1038/s41586-020-2286-9

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

You et al., Structural characterization and SARS-CoV-2 inhibitory activity of a sulfated polysaccharide from Caulerpa lentillifera, Carbohydrate Polymers, doi:10.1016/j.carbpol.2021.119006

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Pham et al., A deep learning framework for high-throughput mechanism-driven phenotype compound screening and its application to COVID-19 drug repurposing, Nature Machine Intelligence, doi:10.1038/s42256-020-00285-9

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Chellasamy et al., Docking and molecular dynamics studies of human ezrin protein with a modelled SARS-CoV-2 endodomain and their interaction with potential invasion inhibitors, Journal of King Saud University - Science, doi:10.1016/j.jksus.2022.102277

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

https://www.jpost.com/health-and-wellness/israeli-scientists-say-their-antiviral-drug-coul..

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Aminpour et al., In Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds, Computation, doi:10.3390/computation10040051

Zhang et al., A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-020-00343-z

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

https://www.biorxiv.org/content/10.1101/2021.09.17.460613v1

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Choe et al., The Efficacy of Traditional Medicinal Plants in Modulating the Main Protease of SARS‐CoV‐2 and Cytokine Storm, Chemistry & Biodiversity, doi:10.1002/cbdv.202200655

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Zhang et al., A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-020-00343-z

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Jose et al., Potential of phytocompounds from Brassica oleracea targeting S2-domain of SARS-CoV-2 spike glycoproteins: Structure and molecular insights, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.132369

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Basu et al., Therapeutics for COVID-19 and post COVID-19 complications: An update, Current Research in Pharmacology and Drug Discovery, doi:10.1016/j.crphar.2022.100086

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

Dinda et al., Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19, European Journal of Medicinal Chemistry Reports, doi:10.1016/j.ejmcr.2022.100079

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Kadioglu et al., Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2021.104359

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Ali et al., Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2, Archiv der Pharmazie, doi:10.1002/ardp.202100360

https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(21)005..

http://www.ichp.vot.pl/index.php/p/article/view/1148

https://www.sciencedirect.com/science/article/pii/S0223523421007066

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Jeong et al., Chemical screen uncovers novel structural classes of inhibitors of the papain-like protease of coronaviruses, iScience, doi:10.1016/j.isci.2022.105254

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Rajamanickam et al., Molecular insight of phytocompounds from Indian spices and its hyaluronic acid conjugates to block SARS-CoV-2 viral entry, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2022.2121757

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Byadi et al., In silico discovery of novel inhibitors from Northern African natural products database against main protease (Mpro) of SARS-CoV-2, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2022.2040594

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Pacl et al., Water-soluble tocopherol derivatives inhibit SARS-CoV-2 RNA-dependent RNA polymerase, bioRxiv, doi:10.1101/2021.07.13.449251

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Li et al., Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2, Computational and Structural Biotechnology Journal, doi:10.1016/j.csbj.2020.08.016

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

https://academic.oup.com/pcm/advance-article/doi/10.1093/pcmedi/pbac024/6713978

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

https://www.sciencedirect.com/science/article/pii/S2772417421000133

Ma et al., Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CLpro, Antiviral Research, doi:10.1016/j.antiviral.2022.105419

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Zhang et al., A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-020-00343-z

Chen et al., The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion, Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.11.022

https://con.antppublishing.com/index.php/ittpcovid19/article/view/183

https://www.mdpi.com/2304-8158/10/9/2084/htm

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Babu et al., Identification of differentially expressed genes and their major pathways among the patient with COVID-19, cystic fibrosis, and chronic kidney disease, Informatics in Medicine Unlocked, doi:10.1016/j.imu.2022.101038

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

Patten et al., Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization., iScience, doi:10.1016/j.isci.2022.104925

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

https://www.sciencedirect.com/science/article/abs/pii/S1094553921000018 (Retrospective Study)

Shahanshah et al., In-silico screening to delineate novel antagonists to SARS-CoV-2 nucleocapsid protein, Physics and Chemistry of the Earth, Parts A/B/C, doi:10.1016/j.pce.2022.103188

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

https://academic.oup.com/qjmed/advance-article/doi/10.1093/qjmed/hcab184/6329274

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

BİLGİNER et al., Molecular Docking Study of Several Seconder Metabolites from Medicinal Plants as Potential Inhibitors of COVID-19 Main Protease, Turkish Journal of Pharmaceutical Sciences, doi:10.4274/tjps.galenos.2021.83548

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

Yang et al., Potential medicinal plants involved in inhibiting 3CLpro activity: A practical alternate approach to combating COVID-19, Journal of Integrative Medicine, doi:10.1016/j.joim.2022.08.001

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

Chen et al., The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion, Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.11.022

Kadioglu et al., Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2021.104359

Zhu et al., Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E, Virology, doi:10.1016/j.virol.2022.04.005

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

Zhu et al., Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E, Virology, doi:10.1016/j.virol.2022.04.005

Yang et al., Potential medicinal plants involved in inhibiting 3CLpro activity: A practical alternate approach to combating COVID-19, Journal of Integrative Medicine, doi:10.1016/j.joim.2022.08.001

https://pubmed.ncbi.nlm.nih.gov/32473509/

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Pillaiyar et al., Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy, Journal of Medicinal Chemistry, doi:10.1021/acs.jmedchem.1c00335

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

Adem et al., Multidimensional in silico strategy for identification of natural polyphenols-based SARS-CoV-2 main protease (Mpro) inhibitors to unveil a hope against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105452

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

Basu et al., Therapeutics for COVID-19 and post COVID-19 complications: An update, Current Research in Pharmacology and Drug Discovery, doi:10.1016/j.crphar.2022.100086

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Li et al., Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2, Computational and Structural Biotechnology Journal, doi:10.1016/j.csbj.2020.08.016

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Mirabelli et al., Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2105815118

Babu et al., Identification of differentially expressed genes and their major pathways among the patient with COVID-19, cystic fibrosis, and chronic kidney disease, Informatics in Medicine Unlocked, doi:10.1016/j.imu.2022.101038

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Arunkumar et al., Marine algal antagonists targeting 3CL protease and spike glycoprotein of SARS-CoV-2: a computational approach for anti-COVID-19 drug discovery, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2021.1921032

Clayton et al., Prophylactic and therapeutic potential zinc metallodrugs drug discovery: Identification of SARS-CoV-2 replication and spike/ACE2 inhibitors, Current Computer-Aided Drug Design, doi:10.2174/1573409918999220921100030

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Bluemling et al., The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N-Hydroxycytidine (EIDD-1931) in a mouse model of lethal Ebola virus infection, Antiviral Research, doi:10.1016/j.antiviral.2022.105453

Xia et al., Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion, Cell Research, doi:10.1038/s41422-020-0305-x

Pham et al., A deep learning framework for high-throughput mechanism-driven phenotype compound screening and its application to COVID-19 drug repurposing, Nature Machine Intelligence, doi:10.1038/s42256-020-00285-9

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Arshad et al., Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1909

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

Ikemura et al., Engineered ACE2 counteracts vaccine-evading SARS-CoV-2 Omicron variant, bioRxiv, doi:10.1101/2021.12.22.473804

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Holubovska et al., RNA polymerase inhibitor enisamium for treatment of moderate COVID-19 patients: a randomized, placebo-controlled, multicenter, double-blind phase 3 clinical trial, medRxiv, doi:10.1101/2022.08.21.22279036

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Mirabelli et al., Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2105815118

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Ravindran et al., Discovery of host-directed modulators of virus infection by probing the SARS-CoV-2–host protein–protein interaction network, Briefings in Bioinformatics, doi:10.1093/bib/bbac456

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Al-Shuhaib et al., Epicatechin is a promising novel inhibitor of SARS-CoV-2 entry by disrupting interactions between angiotensin-converting enzyme type 2 and the viral receptor binding domain: A computational/simulation study, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2021.105155

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Zhou et al., Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, Cell Discovery, doi:10.1038/s41421-020-0153-3

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Aminpour et al., In Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds, Computation, doi:10.3390/computation10040051

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Pillaiyar et al., Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy, Journal of Medicinal Chemistry, doi:10.1021/acs.jmedchem.1c00335

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Mortezaei et al., Variations of SARS-CoV-2 in the Iranian Population and Candidate Putative Drug-like Compounds to Inhibit the Mutated Proteins, Heliyon, doi:10.1016/j.heliyon.2022.e09910

https://www.mdpi.com/1424-8247/14/9/892

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Sund et al., Association between pharmaceutical modulation of oestrogen in postmenopausal women in Sweden and death due to COVID-19: a cohort study, BMJ Open, doi:10.1136/bmjopen-2021-053032

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Babu et al., Identification of differentially expressed genes and their major pathways among the patient with COVID-19, cystic fibrosis, and chronic kidney disease, Informatics in Medicine Unlocked, doi:10.1016/j.imu.2022.101038

https://www.researchsquare.com/article/rs-842564/v1 (In Vitro)

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Mousavi et al., Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies, Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2022/2044282

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

https://www.mdpi.com/1424-8247/14/9/892

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-author..

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

https://www.jpost.com/health-science/covid-90-percent-of-patients-treated-with-new-israeli..

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

https://www.sciencedirect.com/science/article/pii/S2352914822002714

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Arshad et al., Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1909

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Luczkowiak et al., Potent Neutralizing Activity of Polyclonal Equine Antibodies against SARS-CoV-2 Variants of Concern, The Journal of Infectious Diseases, doi:10.1093/infdis/jiac331

Munshi et al., An open-labelled, randomised, controlled, proof of concept clinical trial to evaluate the efficacy of AYUSH interventions (Cap.Torchnil + Tab. Febcin) as add-on therapy in the clinical management of moderate Covid-19 patients, Journal of Ayurveda and Integrative Medicine, doi:10.1016/j.jaim.2022.100559

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

https://www.jcchems.com/index.php/JCCHEMS/article/download/1802/561

Abbas et al., Synthesis and investigation of anti-COVID19 ability of ferrocene Schiff base derivatives by quantum chemical and molecular docking, Journal of Molecular Structure, doi:10.1016/j.molstruc.2021.132242

Haritha et al., Quantum chemical studies on the binding domain of SARS-CoV-2 S-protein: human ACE2 interface complex, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2022.2120537

Gangadharan et al., Repurposing of Potential Antiviral Drugs against RNA-dependent RNA Polymerase of SARS-CoV-2 by Computational Approach, Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.09.007

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

https://elifesciences.org/articles/68165

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

https://flowpharma.com/product/flovid-20/

https://www.sciencedirect.com/science/article/pii/S259009862200029X

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2)

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 And